BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J. 1964;1:89-92. [PMID: 14075156 DOI: 10.1136/bmj.1.5375.89] [Cited by in Crossref: 431] [Cited by in F6Publishing: 422] [Article Influence: 16.6] [Reference Citation Analysis]
Number Citing Articles
1 Luan ZJ, Li Y, Zhao XY, Wang L, Sun YH, Wang SY, Qian JM. Treatment efficacy and safety of low-dose azathioprine in chronic active ulcerative colitis patients: A meta-analysis and systemic review: Low-dose AZA treatment in UC patients. Journal of Digestive Diseases 2016;17:652-9. [DOI: 10.1111/1751-2980.12386] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
2 Annese V, Latiano A, Rossi L, Lombardi G, Dallapiccola B, Serafini S, Damonte G, Andriulli A, Magnani M. Erythrocytes-Mediated Delivery of Dexamethasone in Steroid-Dependent IBD Patients-A Pilot Uncontrolled Study. Am J Gastroenterology 2005;100:1370-5. [DOI: 10.1111/j.1572-0241.2005.41412.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 3.1] [Reference Citation Analysis]
3 van Gennep S, de Boer NK, D'Haens GR, Löwenberg M. Thiopurine Treatment in Ulcerative Colitis: A Critical Review of the Evidence for Current Clinical Practice. Inflamm Bowel Dis 2017;24:67-77. [PMID: 29272488 DOI: 10.1093/ibd/izx025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
4 Palomba S, Manguso F, Orio F, Russo T, Oppedisano R, Sacchinelli A, Falbo A, Tolino A, Zullo F, Mastrantonio P. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study. Menopause 2008;15:730-6. [DOI: 10.1097/gme.0b013e318159f190] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
5 Hogezand RAV, Hees PAMV, Gorp JPWMV, Lier HJJV, Bakker JH, Wesseling P, Haelst UJGMV, Tongeren JHMV. Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis. Alimentary Pharmacology & Therapeutics 1988;2:33-40. [DOI: 10.1111/j.1365-2036.1988.tb00668.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
6 Ho EY, Cominelli F, Katz J. Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It? Curr Treat Options Gastroenterol. 2015;13:130-142. [PMID: 25619458 DOI: 10.1007/s11938-014-0044-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Guimbaud R, Beades E, Chauvelot-moachon L, Quartier G, Gaudric M, Bertrand V, Cellier C, Vidon N, Devaux J, Richard B, Couturier D, Chaussade S. Technetium Tc 99m hexamethyl propylene amine oxine leukocyte scintigraphy in patients with ulcerative colitis: correlation with clinical, biologic, endoscopic, and pathologic intensity, and local release of interleukin 8. Gastrointestinal Endoscopy 1998;48:491-6. [DOI: 10.1016/s0016-5107(98)70090-2] [Cited by in Crossref: 16] [Article Influence: 0.7] [Reference Citation Analysis]
8 Sandborn WJ, Wiesner RH, Tremaine WJ, Larusso NF. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut 1993;34:242-6. [PMID: 8432481 DOI: 10.1136/gut.34.2.242] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 1.8] [Reference Citation Analysis]
9 Campieri M, De Franchis R, Porro GB, Ranzi T, Brunetti G, Barbara L. Mesalazine (5-Aminosalicylic Acid) Suppositories in the Treatment of Ulcerative Proctitis or Distal Proctosigmoiditis: A Randomized Controlled Trial. Scandinavian Journal of Gastroenterology 2009;25:663-8. [DOI: 10.3109/00365529008997590] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
10 Osada T, Arakawa A, Sakamoto N, Ueyama H, Shibuya T, Ogihara T, Yao T, Watanabe S. Autofluorescence imaging endoscopy for identification and assessment of inflammatory ulcerative colitis. World J Gastroenterol 2011; 17(46): 5110-5116 [PMID: 22171146 DOI: 10.3748/wjg.v17.i46.5110] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
11 Dohos D, Hanák L, Szakács Z, Kiss S, Párniczky A, Erőss B, Pázmány P, Hegyi P, Sarlós P. Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2021;53:220-33. [PMID: 33249621 DOI: 10.1111/apt.16182] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Sugi K, Saitoh O, Matsuse R, Tabata K, Uchida K, Kojima K, Nakagawa K, Tanaka S, Teranishi T, Hirata I, Katsu K. Antineutrophil Cytoplasmic Antibodies in Japanese Patients With Inflammatory Bowel Disease: Prevalence and Recognition of Putative Antigens. American Journal of Gastroenterology 1999;94:1304-12. [DOI: 10.1111/j.1572-0241.1999.01081.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
13 Slovak J, Wang C, Sun Y, Otoni C, Morrison J, Deitz K, Levine D, Jergens A. Development and validation of an endoscopic activity score for canine inflammatory bowel disease. The Veterinary Journal 2015;203:290-5. [DOI: 10.1016/j.tvjl.2014.12.030] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
14 Khanna R, Zou G, Feagan BG. Evolution of the Randomized Controlled Trial in Inflammatory Bowel Disease: Current Challenges and Future Solutions. Inflamm Bowel Dis 2018;24:2155-64. [PMID: 29788218 DOI: 10.1093/ibd/izy117] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Travis S, Yap LM, Hawkey C, Warren B, Lazarov M, Fong T, Tesi RJ. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis. 2005;11:713-719. [PMID: 16043985 DOI: 10.1097/01.mib.0000172807.26748.16] [Cited by in Crossref: 82] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
16 Gionchetti P, D’Arienzo A, Rizzello F, Manguso F, Maieron R, Lecis PE, Valpiani D, Iaquinto G, Annese V, Balzano A. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. J Clin Gastroenterol. 2005;39:291-297. [PMID: 15758622 DOI: 10.1097/01.mcg.0000155124.74548.61] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
17 Lauritsen K, Laursen LS, Bukhave K, Rask-madsen J. Does Vitamin E Supplementation Modulate in Vivo Arachidonate Metabolism in Human Inflammation? Pharmacology & Toxicology 1987;61:246-9. [DOI: 10.1111/j.1600-0773.1987.tb01812.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
18 Hurlstone DP, Thomson M, Brown S, Tiffin N, Cross SS, Hunter MD. Confocal endomicroscopy in ulcerative colitis: differentiating dysplasia-associated lesional mass and adenoma-like mass. Clin Gastroenterol Hepatol. 2007;5:1235-1241. [PMID: 17690019 DOI: 10.1016/j.cgh.2007.06.003] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 3.8] [Reference Citation Analysis]
19 Rhodes JM, Robinson R, Beales I, Pugh S, Dickinson R, Dronfield M, Speirs CJ, Wilkinson P, Wilkinson SP. Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis. Aliment Pharmacol Ther 2008;27:228-40. [PMID: 17988236 DOI: 10.1111/j.1365-2036.2007.03569.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
20 Golovics PA, Gonczi L, Reinglas J, Verdon C, Pundir S, Afif W, Wild G, Bitton A, Bessissow T, Lakatos PL. Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study. Dig Dis Sci 2021. [PMID: 34286411 DOI: 10.1007/s10620-021-07178-w] [Reference Citation Analysis]
21 Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988;94:1383-1389. [PMID: 2896139 DOI: 10.1016/0016-5085(88)90677-4] [Cited by in Crossref: 131] [Cited by in F6Publishing: 126] [Article Influence: 3.9] [Reference Citation Analysis]
22 Arai M, Naganuma M, Sugimoto S, Kiyohara H, Ono K, Mori K, Saigusa K, Nanki K, Mutaguchi M, Mizuno S, Bessho R, Nakazato Y, Hosoe N, Matsuoka K, Inoue N, Ogata H, Iwao Y, Kanai T. The Ulcerative Colitis Endoscopic Index of Severity is Useful to Predict Medium- to Long-Term Prognosis in Ulcerative Colitis Patients with Clinical Remission. J Crohns Colitis. 2016;10:1303-1309. [PMID: 27194529 DOI: 10.1093/ecco-jcc/jjw104] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
23 Ge C, Lu Y, Shen H, Zhu L. Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis. Scand J Gastroenterol 2022;:1-12. [PMID: 34994661 DOI: 10.1080/00365521.2021.2022193] [Reference Citation Analysis]
24 Ginsberg AL, Davis ND, Nochomovitz LE. Placebo-controlled trial of ulcerative colitis with oral 4-aminosalicylic acid. Gastroenterology 1992;102:448-52. [PMID: 1290475 DOI: 10.1016/0016-5085(92)90089-h] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
25 Daperno M, Castiglione F, de Ridder L, Dotan I, Färkkilä M, Florholmen J, Fraser G, Fries W, Hebuterne X, Lakatos PL. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis. 2011;5:484-498. [PMID: 21939926 DOI: 10.1016/j.crohns.2011.07.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 6.5] [Reference Citation Analysis]
26 Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kießlich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R. European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn's and Colitis 2013;7:982-1018. [DOI: 10.1016/j.crohns.2013.09.016] [Cited by in Crossref: 486] [Cited by in F6Publishing: 410] [Article Influence: 54.0] [Reference Citation Analysis]
27 Hawthorne AB, Boughton-Smith NK, Whittle BJ, Hawkey CJ. Colorectal leukotriene B4 synthesis in vitro in inflammatory bowel disease: inhibition by the selective 5-lipoxygenase inhibitor BWA4C. Gut 1992;33:513-7. [PMID: 1316305 DOI: 10.1136/gut.33.4.513] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 0.7] [Reference Citation Analysis]
28 Ljung T, Axelsson L, Herulf M, Lundberg JO, Hellström PM. Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn’s colitis in response to infliximab treatment: INFLIXIMAB TREATMENT AND RECTAL NITRIC OXIDE. Alimentary Pharmacology & Therapeutics 2007;25:925-32. [DOI: 10.1111/j.1365-2036.2007.03284.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
29 Bansky G, Bühler H, Stamm B, Häcki WH, Buchmann P, Müller J. Treatment of distal ulcerative colitis with beclomethasone enemas: High therapeutic efficacy without endocrine side effects: A prospective, randomized, double-blind trial. Diseases of the Colon & Rectum 1987;30:288-92. [DOI: 10.1007/bf02556177] [Cited by in Crossref: 45] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
30 Ament ME. Inflammatory disease of the colon: Ulcerative colitis and Crohn's colitis. The Journal of Pediatrics 1975;86:322-34. [DOI: 10.1016/s0022-3476(75)80958-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
31 Dick AP, Holt LP, Dalton ER. Persistence of mucosal abnormality in ulcerative colitis. Gut 1966;7:355-60. [PMID: 5917422 DOI: 10.1136/gut.7.4.355] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 0.6] [Reference Citation Analysis]
32 Vuitton L, Peyrin-Biroulet L, Colombel JF, Pariente B, Pineton de Chambrun G, Walsh AJ, Panes J, Travis SP, Mary JY, Marteau P. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther. 2017;45:801-813. [PMID: 28112419 DOI: 10.1111/apt.13948] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 10.8] [Reference Citation Analysis]
33 Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, van Assche G. [Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)]. Rev Gastroenterol Mex 2014;79:263-89. [PMID: 25487134 DOI: 10.1016/j.rgmx.2014.10.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
34 D'Arienzo A, Scaglione G, Vicinanza G, Manguso F, Bennato R, Belfiore G, Imbriaco M, Mazzacca G. Magnetic resonance imaging with ferumoxil, a negative superparamagnetic oral contrast agent, in the evaluation of ulcerative colitis. Am J Gastroenterol 2000;95:720-4. [PMID: 10710064 DOI: 10.1111/j.1572-0241.2000.01841.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
35 Caprilli R, Latella G, Frieri G. Treatment of inflammatory bowel diseases: to heal the wound or to heal the sick? J Crohns Colitis 2012;6:621-5. [PMID: 22425510 DOI: 10.1016/j.crohns.2012.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
36 Paspatis GA, Millar A, Chlouverakis GJ, Jamieson CP, Swain PC. Interobserver Variation in Describing Endoscopic Features in Inflammatory Bowel Disease Using Videotapes of Colonoscopy. American Journal of Gastroenterology 2000;95:1376-7. [DOI: 10.1111/j.1572-0241.2000.02051.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
37 Freeman HJ. Limitations in assessment of mucosal healing in inflammatory bowel disease. World J Gastroenterol 2010; 16(1): 15-20 [PMID: 20039444 DOI: 10.3748/wjg.v16.i1.15] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
38 Hodgson HJF, Mazlam MZ. Review article: assessment of drug therapy in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 1991;5:555-84. [DOI: 10.1111/j.1365-2036.1991.tb00525.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
39 Yamamoto-furusho J, Bozada-gutiérrez K, Sánchez-rodríguez A, Bojalil-romano F, Barreto-zuñiga R, Martínez-benitez B. Validación de un nuevo índice integral de enfermedad para evaluar el grado de actividad en pacientes mexicanos con colitis ulcerosa: un estudio de cohorte prospectivo. Revista de Gastroenterología de México 2019;84:317-25. [DOI: 10.1016/j.rgmx.2018.07.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Creed TJ, Probert CS, Norman MN, Moorghen M, Shepherd NA, Hearing SD, Dayan CM; BASBUC INVESTIGATORS. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther. 2006;23:1435-1442. [PMID: 16669958 DOI: 10.1111/j.1365-2036.2006.02904.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 4.4] [Reference Citation Analysis]
41 Connell A, Lennard-jones J, Misiewicz J, Baron J, Jones F. COMPARISON OF ACETARSOL AND PREDNISOLONE-21-PHOSPHATE SUPPOSITORIES IN THE TREATMENT OF IDIOPATHIC PROCTITIS. The Lancet 1965;285:238-9. [DOI: 10.1016/s0140-6736(65)91523-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
42 Walker AW, Sanderson JD, Churcher C, Parkes GC, Hudspith BN, Rayment N, Brostoff J, Parkhill J, Dougan G, Petrovska L. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011;11:7. [PMID: 21219646 DOI: 10.1186/1471-2180-11-7] [Cited by in Crossref: 415] [Cited by in F6Publishing: 385] [Article Influence: 37.7] [Reference Citation Analysis]
43 Ito H, Iida M, Matsumoto T, Suzuki Y, Sasaki H, Yoshida T, Takano Y, Hibi T. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis. 2010;16:1567-1574. [PMID: 20049950 DOI: 10.1002/ibd.21193] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
44 Mawdsley JE, Jenkins DG, Macey MG, Langmead L, Rampton DS. The effect of hypnosis on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Am J Gastroenterol. 2008;103:1460-1469. [PMID: 18510607 DOI: 10.1111/j.1572-0241.2008.01845.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
45 Conn HO, Spencer RP. Observer Error in Liver Scans. Gastroenterology 1972;62:1085-90. [DOI: 10.1016/s0016-5085(72)80126-4] [Cited by in Crossref: 26] [Article Influence: 0.5] [Reference Citation Analysis]
46 Bortoluzzi F, Valentini M, Cernigoi C, Toffoli G, Boiocchi M, Poletti M, Sozzi M, Fornasarig M, Cannizzaro R, Bertolissi E. DNA flow cytometric evaluation of cell cycle distribution in ulcerative colitis: a proposed method for assessing severity of disease. Gut 1995;36:50-4. [PMID: 7890236 DOI: 10.1136/gut.36.1.50] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
47 Guirgis M, Wendt E, Wang LM, Walsh A, Burger D, Bryant RV, Kent A, Adamson R, Brain O, Travis SPL, Keshav S. Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis. ECCOJC. [DOI: 10.1093/ecco-jcc/jjw174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
48 Lee DA, Taylor GM, James VH, Walker G. Plasma prednisolone levels and adrenocortical responsiveness after administration of prednisolone-21-phosphate as a retention enema. Gut 1979;20:349-55. [PMID: 223947 DOI: 10.1136/gut.20.5.349] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 0.9] [Reference Citation Analysis]
49 Priebe WM, Dacosta LR, Beck IT. Is epigastric tenderness a sign of peptic ulcer disease? Gastroenterology 1982;82:16-9. [DOI: 10.1016/0016-5085(82)90116-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
50 Travis SPL, Higgins PDR, Orchard T, Van Der Woude CJ, Panaccione R, Bitton A, O’morain C, Panés J, Sturm A, Reinisch W, Kamm MA, D’haens G. Review article: defining remission in ulcerative colitis: Review: remission in ulcerative colitis. Alimentary Pharmacology & Therapeutics 2011;34:113-24. [DOI: 10.1111/j.1365-2036.2011.04701.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 103] [Article Influence: 10.3] [Reference Citation Analysis]
51 Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008;14:5584-559; discussion 5588. [PMID: 18810778 DOI: 10.3784/wjg.14.5584] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Leung Y, Panaccione R, Hemmelgarn B, Jones J. Exposing the Weaknesses: A Systematic Review of Azathioprine Efficacy in Ulcerative Colitis. Dig Dis Sci 2008;53:1455-61. [DOI: 10.1007/s10620-007-0036-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
53 Langley BO, Guedry SE, Goldenberg JZ, Hanes DA, Beardsley JA, Ryan JJ. Inflammatory Bowel Disease and Neutrophil-Lymphocyte Ratio: A Systematic Scoping Review. J Clin Med 2021;10:4219. [PMID: 34575330 DOI: 10.3390/jcm10184219] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Baldassano RN, Lichtenstein GR. The New Endoscopy of Ulcerative Colitis. Gastrointestinal Endoscopy 1997;46:468-71. [DOI: 10.1016/s0016-5107(97)70047-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
55 Dhingra R, Kedia S, Mouli VP, Garg SK, Singh N, Bopanna S, Singla V, Choudhury BN, Verma P, Tiwari V, Gupta SD, Makharia G, Ahuja V. Evaluating clinical, dietary, and psychological risk factors for relapse of ulcerative colitis in clinical, endoscopic, and histological remission: Predicting relapse in ulcerative colitis. Journal of Gastroenterology and Hepatology 2017;32:1698-705. [DOI: 10.1111/jgh.13770] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
56 Smedh K, Olaison G, Jonsson KA, Johansson KE, Skullman S, Hallbook O. Interobserver Variation of Colonoileoscopic Findings in Crohn's Disease. Scandinavian Journal of Gastroenterology 2009;30:81-6. [DOI: 10.3109/00365529509093240] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
57 Hjortswang H, Ström M, Almer S. Health-related quality of life in Swedish patients with ulcerative colitis. Am J Gastroenterol. 1998;93:2203-2211. [PMID: 9820397 DOI: 10.1111/j.1572-0241.1998.00537.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 2.0] [Reference Citation Analysis]
58 Simmonds NJ, Allen RE, Stevens TR, Niall R, Van Someren M, Blake DR, Rampton DS. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology 1992;103:186-96. [DOI: 10.1016/0016-5085(92)91112-h] [Cited by in Crossref: 241] [Cited by in F6Publishing: 81] [Article Influence: 8.0] [Reference Citation Analysis]
59 Eshuis EJ, Bemelman WA, Stokkers PC. Infliximab for the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;3:219-29. [DOI: 10.1586/egh.09.19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
60 Wiernicka A, Szymanska S, Cielecka-Kuszyk J, Dadalski M, Kierkus J. Histological healing after infliximab induction therapy in children with ulcerative colitis. World J Gastroenterol 2015; 21(37): 10654-10661 [PMID: 26457025 DOI: 10.3748/wjg.v21.i37.10654] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
61 Kuwata G, Kamisawa T, Koizumi K, Tabata T, Hara S, Kuruma S, Fujiwara T, Chiba K, Egashira H, Fujiwara J, Arakawa T, Momma K, Horiguchi S. Ulcerative colitis and immunoglobulin G4. Gut Liver 2014;8:29-34. [PMID: 24516698 DOI: 10.5009/gnl.2014.8.1.29] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
62 Ikeya K, Hanai H, Sugimoto K, Osawa S, Kawasaki S, Iida T, Maruyama Y, Watanabe F. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. J Crohns Colitis. 2016;10:286-295. [PMID: 26581895 DOI: 10.1093/ecco-jcc/jjv210] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 9.1] [Reference Citation Analysis]
63 Kjeldsen J, Lauritsen K, De Muckadell OB. Serum concentrations of orosomucoid: improved decision-making for tapering prednisolone therapy in patients with active inflammatory bowel disease? Scand J Gastroenterol. 1997;32:933-941. [PMID: 9299674 DOI: 10.3109/00365529709011205] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
64 Silva AD, Tsironi E, Feakins RM, Rampton DS. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther 2005;22:1097-105. [DOI: 10.1111/j.1365-2036.2005.02700.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 3.9] [Reference Citation Analysis]
65 Kopelman Y, Siersema PD, Nir Y, Szold A, Bapaye A, Segol O, Willenz EP, Lelcuk S, Geller A, Kopelman D. Endoluminal compression clip: full-thickness resection of the mesenteric bowel wall in a porcine model. Gastrointest Endosc. 2009;70:1146-1157. [PMID: 19647245 DOI: 10.1016/j.gie.2009.05.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
66 Polese L, Boetto R, De Franchis G, Angriman I, Porzionato A, Norberto L, Sturniolo GC, Macchi V, De Caro R, Merigliano S. B1a lymphocytes in the rectal mucosa of ulcerative colitis patients. World J Gastroenterol 2012; 18(2): 144-149 [PMID: 22253520 DOI: 10.3748/wjg.v18.i2.144] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
67 Lee JS, Kim ES, Moon W. Chronological Review of Endoscopic Indices in Inflammatory Bowel Disease. Clin Endosc. 2018;. [PMID: 30130840 DOI: 10.5946/ce.2018.042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
68 Paoluzi O, Crispino P, Amantea A, Pica R, Iacopini F, Consolazio A, Di Palma V, Rivera M, Paoluzi P. Diffuse febrile dermatosis in a patient with active ulcerative colitis under treatment with steroids and azathioprine: a case of Sweet’s syndrome. Digestive and Liver Disease 2004;36:361-6. [DOI: 10.1016/j.dld.2003.10.020] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
69 Powell-Tuck J, Day DW, Buckell NA, Wadsworth J, Lennard-Jones JE. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci. 1982;27:533-537. [PMID: 6979471 DOI: 10.1007/bf01296733] [Cited by in Crossref: 133] [Cited by in F6Publishing: 47] [Article Influence: 3.3] [Reference Citation Analysis]
70 Chen QK, Yuan SZ, Wen ZF, Zhong YQ, Li CJ, Wu HS, Mai CR, Xie PY, Lu YM, Yu ZL. Characteristics and therapeutic efficacy of sulfasalazine in patients with mildly and moderately active ulcerative colitis. World J Gastroenterol 2005; 11(16): 2462-2466 [PMID: 15832418 DOI: 10.3748/wjg.v11.i16.2462] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
71 Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Sociale O, Papa A, De Vitis I, Rapaccini GL, Guidi L. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis. 2013;19:1065-1072. [PMID: 23448790 DOI: 10.1097/mib.0b013e3182802909] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 5.9] [Reference Citation Analysis]
72 Giacomelli R, Parzanese I, Frieri G, Passacantando A, Pizzuto F, Pimpo T, Cipriani P, Viscido A, Caprilli R, Tonietti G. Increase of circulating gamma/delta T lymphocytes in the peripheral blood of patients affected by active inflammatory bowel disease. Clin Exp Immunol 1994;98:83-8. [PMID: 7923890 DOI: 10.1111/j.1365-2249.1994.tb06611.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 1.4] [Reference Citation Analysis]
73 Chan G, Fefferman DS, Farrell RJ. Endoscopic assessment of inflammatory bowel disease: colonoscopy/esophagogastroduodenoscopy. Gastroenterol Clin North Am 2012;41:271-90. [PMID: 22500517 DOI: 10.1016/j.gtc.2012.01.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
74 Uguccioni M, Gionchetti P, Robbiani DF, Rizzello F, Peruzzo S, Campieri M, Baggiolini M. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol. 1999;155:331-336. [PMID: 10433925 DOI: 10.1016/s0002-9440(10)65128-0] [Cited by in Crossref: 194] [Cited by in F6Publishing: 69] [Article Influence: 8.4] [Reference Citation Analysis]
75 Egan L, Sandborn W, Mays D, Tremaine W, Fauq A, Lipsky J. Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. Clinical Pharmacology & Therapeutics 1999;65:29-39. [DOI: 10.1016/s0009-9236(99)70119-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
76 Loftus EV Jr, Tremaine WJ, Nelson RA, Shoemaker JD, Sandborn WJ, Phillips SF, Hasan Y. Dexpanthenol enemas in ulcerative colitis: a pilot study. Mayo Clin Proc 1997;72:616-20. [PMID: 9212762 DOI: 10.1016/S0025-6196(11)63566-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
77 Walujkar SA, Dhotre DP, Marathe NP, Lawate PS, Bharadwaj RS, Shouche YS. Characterization of bacterial community shift in human Ulcerative Colitis patients revealed by Illumina based 16S rRNA gene amplicon sequencing. Gut Pathog. 2014;6:22. [PMID: 25018784 DOI: 10.1186/1757-4749-6-22] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 6.8] [Reference Citation Analysis]
78 Kishore J, Ghoshal U, Ghoshal UC, Krishnani N, Kumar S, Singh M, Ayyagari A. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. Journal of Medical Microbiology 2004;53:1155-60. [DOI: 10.1099/jmm.0.45629-0] [Cited by in Crossref: 137] [Cited by in F6Publishing: 138] [Article Influence: 7.6] [Reference Citation Analysis]
79 Paoluzi OA, Crispino P, Rivera M, Iacopini F, Palladini D, Consolazio A, Paoluzi P. Skeletal muscle disorders associated with inflammatory bowel diseases: occurrence of myositis in a patient with ulcerative colitis and Hashimoto's thyroiditis--case report and review of the literature. Int J Colorectal Dis 2006;21:473-7. [PMID: 16205931 DOI: 10.1007/s00384-005-0035-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
80 Camilleri M, Proano M. Advances in the assessment of disease activity in inflammatory bowel disease. Mayo Clin Proc 1989;64:800-7. [PMID: 2671519 DOI: 10.1016/s0025-6196(12)61753-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
81 van Bergeijk JD, Wilson JH, Nielsen OH, von Tirpitz C, Karvonen AL, Lygren I, Rädler A, Waldum HL, Mulder CJ, Friis S, Tefera S, Hoogkamer JF; OPUS 1 study group. Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1). Eur J Gastroenterol Hepatol 2002;14:243-8. [PMID: 11953688 DOI: 10.1097/00042737-200203000-00007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
82 Ando T, Takahashi H, Watanabe O, Maeda O, Ishiguro K, Ishikawa D, Hasegawa M, Ohmiya N, Niwa Y, Goto H. Magnifying chromoscopy, a novel and useful technique for colonoscopy in ulcerative colitis. World J Gastroenterol 2007; 13(18): 2523-2528 [PMID: 17551998 DOI: 10.3748/wjg.v13.i18.2523] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
83 Vanderhoof JA, Ament ME. Proctosigmoidoscopy and rectal biopsy in infants and children. The Journal of Pediatrics 1976;89:911-5. [DOI: 10.1016/s0022-3476(76)80595-1] [Cited by in Crossref: 9] [Article Influence: 0.2] [Reference Citation Analysis]
84 Lehy T, Mignon M, Abitbol JL. Epithelial cell proliferation in the rectal stump of patients with ileorectal anastomosis for ulcerative colitis. Gut 1983;24:1048-56. [PMID: 6629115 DOI: 10.1136/gut.24.11.1048] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 0.5] [Reference Citation Analysis]
85 Lichtenstein JL. Accuracy and reliability of endoscopy and x-ray in upper gastrointestinal bleeding. Dig Dis Sci 1981;26:70S-5S. [PMID: 6765054 DOI: 10.1007/BF01300811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
86 Kusakcioglu O, Kusakcioglu A, Oz F. Idiopathic ulcerative colitis in Istanbul: clinical review of 204 cases. Dis Colon Rectum 1979;22:350-5. [PMID: 467205 DOI: 10.1007/BF02609325] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
87 Behm BW, Bickston SJ, Bickston SJ. Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd007571] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
88 Stadnicki A, Gonciarz M, Niewiarowski TJ, Hartleb J, Rudnicki M, Merrell NB, Dela Cadena RA, Colman RW. Activation of plasma contact and coagulation systems and neutrophils in the active phase of ulcerative colitis. Dig Dis Sci 1997;42:2356-66. [PMID: 9398817 DOI: 10.1023/a:1018891323205] [Cited by in Crossref: 32] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
89 Naganuma M, Yahagi N, Bessho R, Ohno K, Arai M, Mutaguchi M, Mizuno S, Fujimoto A, Uraoka T, Shimoda M, Hosoe N, Ogata H, Kanai T. Evaluation of the severity of ulcerative colitis using endoscopic dual red imaging targeting deep vessels. Endosc Int Open 2017;5:E76-82. [PMID: 28180151 DOI: 10.1055/s-0042-119393] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
90 Polese L, Angriman I, Cecchetto A, Norberto L, Scarpa M, Ruffolo C, Barollo M, Sommariva A, D'Amico DF. The role of CD40 in ulcerative colitis: histochemical analysis and clinical correlation. Eur J Gastroenterol Hepatol. 2002;14:237-241. [PMID: 11953687 DOI: 10.1097/00042737-200203000-00006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.4] [Reference Citation Analysis]
91 Radeke HH, Stein J, Van Assche G, Rogler G, Lakatos PL, Muellershausen F, Moulin P, Jarvis P, Colin L, Gergely P, Kruis W. A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis. Inflamm Intest Dis 2020;5:180-90. [PMID: 33313070 DOI: 10.1159/000509393] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
92 Ardizzone S, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, Marmo R, Massari A, Molteni P, Maconi G, Porro GB. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011; 9: 483-489. e3. [PMID: 21195796 DOI: 10.1016/j.cgh.2010.12.028] [Cited by in Crossref: 169] [Cited by in F6Publishing: 157] [Article Influence: 14.1] [Reference Citation Analysis]
93 Sharma MP, Duphare HV. 4-Aminosalicylic acid enemas for ulcerative colitis. Lancet 1989;1:450. [PMID: 2563834 DOI: 10.1016/s0140-6736(89)90056-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
94 Teague RH, Salmon PR, Read AE. Fibreoptic examination of the colon: a review of 255 cases. Gut 1973;14:139-42. [PMID: 4540492 DOI: 10.1136/gut.14.2.139] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 1.3] [Reference Citation Analysis]
95 Asonuma K, Kobayashi T, Nakano M, Sagami S, Kiyohara H, Matsubayashi M, Morikubo H, Miyatani Y, Okabayashi S, Yamazaki H, Kuroki Y, Hibi T. Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis. Inflamm Bowel Dis 2021:izab062. [PMID: 33847348 DOI: 10.1093/ibd/izab062] [Reference Citation Analysis]
96 Hjortswang H, Järnerot G, Curman B, Sandberg-Gertzén H, Tysk C, Blomberg B, Almer S, Ström M. The influence of demographic and disease-related factors on health-related quality of life in patients with ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15:1011-1020. [PMID: 12923375 DOI: 10.1097/00042737-200309000-00012] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 3.2] [Reference Citation Analysis]
97 Polese L, De Franchis G, Scarpa M, Sturniolo GC, Ruffolo C, Norberto L, Frego M, D'Amico DF, Angriman I. B1a lymphocytes in ulcerative colitis. Int J Colorectal Dis. 2007;22:1005-1011. [PMID: 17372743 DOI: 10.1007/s00384-007-0298-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
98 Parente F, Molteni M, Marino B, Colli A, Ardizzone S, Greco S, Sampietro G, Foschi D, Gallus S. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis? Am J Gastroenterol. 2010;105:1150-1157. [PMID: 19997096 DOI: 10.1038/ajg.2009.672] [Cited by in Crossref: 81] [Cited by in F6Publishing: 64] [Article Influence: 6.2] [Reference Citation Analysis]
99 Mahida YR, Lamming CE, Gallagher A, Hawthorne AB, Hawkey CJ. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut. 1991;32:50-54. [PMID: 1846838 DOI: 10.1136/gut.32.1.50] [Cited by in Crossref: 99] [Cited by in F6Publishing: 95] [Article Influence: 3.2] [Reference Citation Analysis]
100 Rizzello F, Gionchetti P, Galeazzi R, Novelli G, Valpiani D, D’arienzo A, Manguso F, Castiglione G, Varoli G, Campieri M. Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: A dose-finding study. Adv Therapy 2001;18:261-71. [DOI: 10.1007/bf02850196] [Cited by in Crossref: 31] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
101 Farthing MJ, Lennard-jones JE. Sensibility of the rectum to distension and the anorectal distension reflex in ulcerative colitis. Gut 1978;19:64-9. [PMID: 304827 DOI: 10.1136/gut.19.1.64] [Cited by in Crossref: 196] [Cited by in F6Publishing: 174] [Article Influence: 4.5] [Reference Citation Analysis]
102 van Hees PA, Bakker JH, van Tongeren JH. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut. 1980;21:632-635. [PMID: 6107263 DOI: 10.1136/gut.21.7.632] [Cited by in Crossref: 245] [Cited by in F6Publishing: 240] [Article Influence: 6.0] [Reference Citation Analysis]
103 Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, Scott BB, Lennard-Jones JE. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305:20-22. [PMID: 1638191 DOI: 10.1136/bmj.3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Bickston SJ, Behm BW, Tsoulis DJ, Cheng J, MacDonald JK, Khanna R, Feagan BG. Vedolizumab for induction and maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2014;8:CD007571. [PMID: 25105240 DOI: 10.1002/14651858.cd007571.pub2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
105 Hodgson HJ. Assessment of drug therapy in inflammatory bowel disease. Br J Clin Pharmacol 1982;14:159-70. [PMID: 7049211 DOI: 10.1111/j.1365-2125.1982.tb01957.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.5] [Reference Citation Analysis]
106 Seo M, Okada M, Maeda K, Oh K. Correlation between endoscopic severity and the clinical activity index in ulcerative colitis. American Journal of Gastroenterology 1998;93:2124-9. [DOI: 10.1111/j.1572-0241.1998.00607.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.3] [Reference Citation Analysis]
107 Iacucci M, Panaccione R. Recent advances in the endoscopic assessment of ulcerative colitis. Techniques in Gastrointestinal Endoscopy 2016;18:116-22. [DOI: 10.1016/j.tgie.2016.08.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
108 Davies PS, Rhodes J, Heatley RV, Owen E. Metronidazole in the treatment of chronic proctitis: a controlled trial. Gut 1977;18:680-1. [PMID: 330354 DOI: 10.1136/gut.18.8.680] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 0.8] [Reference Citation Analysis]
109 Ma R, Meng R, Zhang X, Sun Z, Lei Y. Correlation between fecal calprotectin, ulcerative colitis endoscopic index of severity and clinical outcome in patients with acute severe colitis. Exp Ther Med 2020;20:1498-504. [PMID: 32765673 DOI: 10.3892/etm.2020.8861] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
110 Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635-639. [PMID: 10466665 DOI: 10.1016/s0140-6736(98)06343-0] [Cited by in Crossref: 761] [Cited by in F6Publishing: 218] [Article Influence: 33.1] [Reference Citation Analysis]
111 Mazzuoli S, Guglielmi FW, Antonelli E, Salemme M, Bassotti G, Villanacci V. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis. 2013;45:969-977. [PMID: 23932331 DOI: 10.1016/j.dld.2013.06.010] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 8.1] [Reference Citation Analysis]
112 Probert CS, Hearing SD, Schreiber S, Kühbacher T, Ghosh S, Arnott ID, Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998-1002. [PMID: 12801957 DOI: 10.1136/gut.52.7.998] [Cited by in Crossref: 233] [Cited by in F6Publishing: 224] [Article Influence: 12.3] [Reference Citation Analysis]
113 Denton AS, Andreyev HJ, Forbes A, Maher EJ. Systematic review for non-surgical interventions for the management of late radiation proctitis. Br J Cancer. 2002;87:134-143. [PMID: 12107832 DOI: 10.1038/sj.bjc.6600360] [Cited by in Crossref: 96] [Cited by in F6Publishing: 84] [Article Influence: 4.8] [Reference Citation Analysis]
114 Lauritsen K, Hansen J, Bytzer P, Bukhave K, Rask-Madsen J. Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls. Gut 1984;25:1271-8. [PMID: 6149981 DOI: 10.1136/gut.25.11.1271] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 1.7] [Reference Citation Analysis]
115 Gilroy L, Allen PB. Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease? Clin Exp Gastroenterol 2014;7:163-72. [PMID: 24899819 DOI: 10.2147/CEG.S45261] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
116 Gertner DJ, Rampton DS, Stevens TR, Lennard-Jones JE. Verapamil inhibits in-vitro leucotriene B4 release by rectal mucosa in active ulcerative colitis. Aliment Pharmacol Ther 1992;6:163-8. [PMID: 1318088 DOI: 10.1111/j.1365-2036.1992.tb00259.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
117 Smith LA, Baraza W, Tiffin N, Cross SS, Hurlstone DP. Endoscopic resection of adenoma-like mass in chronic ulcerative colitis using a combined endoscopic mucosal resection and cap assisted submucosal dissection technique. Inflamm Bowel Dis. 2008;14:1380-1386. [PMID: 18465807 DOI: 10.1002/ibd.20497] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
118 Rogers BH, Clark LM, Kirsner JB. The epidemiologic and demographic characteristics of inflammatory bowel disease: an analysis of a computerized file of 1400 patients. J Chronic Dis. 1971;24:743-773. [PMID: 5146188 DOI: 10.1016/0021-9681(71)90087-7] [Cited by in Crossref: 116] [Cited by in F6Publishing: 105] [Article Influence: 2.3] [Reference Citation Analysis]
119 Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990. [PMID: 23040452 DOI: 10.1016/j.crohns.2012.09.003] [Cited by in Crossref: 539] [Cited by in F6Publishing: 479] [Article Influence: 53.9] [Reference Citation Analysis]
120 Loftus EV, Tremaine WJ, Nelson RA, Shoemaker JD, Sandborn WJ, Phillips SF, Hasan Y. Dexpanthenol Enemas in Ulcerative Colitis: A Pilot Study. Mayo Clinic Proceedings 1997;72:616-20. [DOI: 10.4065/72.7.616] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
121 Butt JH. Outpatient management of inflammatory bowel disease: Let's keep it as simple as possible. Postgraduate Medicine 2016;92:69-94. [DOI: 10.1080/00325481.1992.11701512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
122 Bossa F, Annese V, Valvano MR, Latiano A, Martino G, Rossi L, Magnani M, Palmieri O, Serafini S, Damonte G, De Santo E, Andriulli A. Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. Inflamm Bowel Dis 2013;19:1872-9. [PMID: 23714676 DOI: 10.1097/MIB.0b013e3182874065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
123 Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lémann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY, Sandborn WJ. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61:535-42. [PMID: 21997563 DOI: 10.1136/gutjnl-2011-300486] [Cited by in Crossref: 295] [Cited by in F6Publishing: 254] [Article Influence: 26.8] [Reference Citation Analysis]
124 Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103-1108. [PMID: 10468688 DOI: 10.1046/j.1365-2036.1999.00560.x] [Cited by in Crossref: 372] [Cited by in F6Publishing: 335] [Article Influence: 16.2] [Reference Citation Analysis]
125 Hafer A, Krämer S, Duncker S, Krüger M, Manns MP, Bischoff SC. Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. BMC Gastroenterol. 2007;7:36. [PMID: 17784949 DOI: 10.1186/1471-230x-7-36] [Cited by in Crossref: 53] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
126 Rodrigues BL, Mazzaro MC, Nagasako CK, Ayrizono MLS, Fagundes JJ, Leal RF. Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores. World J Gastrointest Endosc 2020; 12(12): 504-520 [PMID: 33362904 DOI: 10.4253/wjge.v12.i12.504] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
127 Hackett RP, Ducharme NG, Fubini SL, Erb HN. The Reliability of Endoscopic Examination in Assessment of Arytenoid Cartilage Movement in Horses Part I: Subjective and Objective Laryngeal Evaluation. Vet Surgery 1991;20:174-9. [DOI: 10.1111/j.1532-950x.1991.tb00331.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
128 Frieri G, Pimpo M, Galletti B, Palumbo G, Corrao G, Latella G, Chiaramonte M, Caprilli R. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Dig Liver Dis. 2005;37:92-96. [PMID: 15733520 DOI: 10.1016/j.dld.2004.09.017] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
129 Rampton DS, Brown MJ, Causon R, Sahib M. The effect of disodium cromoglycate on rectal mucosal histamine release, eosinophil exudation and disease activity in active ulcerative colitis. Clin Allergy. 1982;12:243-248. [PMID: 6179653 DOI: 10.1111/j.1365-2222.1982.tb02524.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
130 Ciccocioppo R, Racca F, Paolucci S, Campanini G, Pozzi L, Betti E, Riboni R, Vanoli A, Baldanti F, Corazza GR. Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: Need for mucosal viral load measurement. World J Gastroenterol 2015; 21(6): 1915-1926 [PMID: 25684960 DOI: 10.3748/wjg.v21.i6.1915] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 40] [Article Influence: 6.1] [Reference Citation Analysis]
131 Lauritsen K, Laursen LS, Bukhave K, Rask-madsen J. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986;91:837-44. [DOI: 10.1016/0016-5085(86)90684-0] [Cited by in Crossref: 181] [Cited by in F6Publishing: 179] [Article Influence: 5.0] [Reference Citation Analysis]
132 Ostermann AL, Wunderlich CM, Schneiders L, Vogt MC, Woeste MA, Belgardt BF, Niessen CM, Martiny B, Schauss AC, Frommolt P, Nikolaev A, Hövelmeyer N, Sears RC, Koch PJ, Günzel D, Brüning JC, Wunderlich FT. Intestinal insulin/IGF1 signalling through FoxO1 regulates epithelial integrity and susceptibility to colon cancer. Nat Metab 2019;1:371-89. [PMID: 32694718 DOI: 10.1038/s42255-019-0037-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
133 Hurlstone DP, Sanders DS, Lobo AJ, McAlindon ME, Cross SS. Prospective evaluation of high-frequency mini-probe ultrasound colonoscopic imaging in ulcerative colitis: a valid tool for predicting clinical severity. Eur J Gastroenterol Hepatol 2005;17:1325-31. [PMID: 16292085 DOI: 10.1097/00042737-200512000-00010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
134 Stevens TR, James JP, Simmonds NJ, McCarthy DA, Laurenson IF, Maddison PJ, Rampton DS. Circulating von Willebrand factor in inflammatory bowel disease. Gut 1992;33:502-6. [PMID: 1582595 DOI: 10.1136/gut.33.4.502] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 1.9] [Reference Citation Analysis]
135 Poole CD, Connolly MP, Nielsen SK, Currie CJ, Marteau P. A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis. J Crohns Colitis. 2010;4:275-282. [PMID: 21122516 DOI: 10.1016/j.crohns.2009.11.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
136 Hodgson HJF, Bhatti M. Assessment of Disease Activity in Ulcerative Colitis and Crohnʼs Disease: . Inflammatory Bowel Diseases 1995;1:117-34. [DOI: 10.1097/00054725-199506000-00005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
137 Kim YS, Kim YH, Kim JS, Cheon JH, Ye BD, Jung SA, Park YS, Choi CH, Jang BI, Han DS. The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. J Clin Gastroenterol. 2012;46:51-56. [PMID: 21552140 DOI: 10.1097/mcg.0b013e3182160c9c] [Cited by in Crossref: 60] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
138 Rustemovic N, Cukovic-Cavka S, Brinar M, Radić D, Opacic M, Ostojic R, Vucelic B. A pilot study of transrectal endoscopic ultrasound elastography in inflammatory bowel disease. BMC Gastroenterol 2011;11:113. [PMID: 22014337 DOI: 10.1186/1471-230X-11-113] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
139 Campieri, Cottone, Miglio, Manenti, Astegiano, D’arienzo, Manguso, D’albasio, Bonanomi, Galeazzi, Orlando, Castiglione, Gionchetti. Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis: BECLOMETHASONE ENEMAS IN DISTAL ULCERATIVE COLITIS. Alimentary Pharmacology & Therapeutics 1998;12:361-6. [DOI: 10.1046/j.1365-2036.1998.00299.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
140 Gledhill T, Bodger K. New and emerging treatments for ulcerative colitis: a focus on vedolizumab. Biologics. 2013;7:123-130. [PMID: 23723689 DOI: 10.2147/btt.s30416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
141 Pimpo M, Galletti B, Palumbo G, Viscido A, Gentile P, Caprilli R, Frieri G. Mesalazine vanishing time from rectal mucosa following its topical administration. Journal of Crohn's and Colitis 2010;4:102-5. [DOI: 10.1016/j.crohns.2009.08.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
142 Pullan RD, Ganesh S, Mani V, Morris J, Evans BK, Williams GT, Rhodes J. Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial. Gut 1993;34:676-9. [PMID: 8504970 DOI: 10.1136/gut.34.5.676] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 1.6] [Reference Citation Analysis]
143 Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology. 2007;132:516-526. [PMID: 17258720 DOI: 10.1053/j.gastro.2006.12.037] [Cited by in Crossref: 102] [Cited by in F6Publishing: 86] [Article Influence: 6.4] [Reference Citation Analysis]
144 Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670. [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008] [Cited by in Crossref: 682] [Cited by in F6Publishing: 563] [Article Influence: 170.5] [Reference Citation Analysis]
145 Tun GSZ, Raza M, Hale MF, Lobo AJ. Polymerase chain reaction for detection of mucosal cytomegalovirus infection in patients with acute ulcerative colitis. Ann Gastroenterol 2019;32:81-7. [PMID: 30598596 DOI: 10.20524/aog.2018.0318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
146 Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;20:CD004115. [PMID: 20091560 DOI: 10.1002/14651858.cd004115.pub2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
147 Walsh AJ, Ghosh A, Brain AO, Buchel O, Burger D, Thomas S, White L, Collins GS, Keshav S, Travis SP. Comparing disease activity indices in ulcerative colitis. J Crohns Colitis. 2014;8:318-325. [PMID: 24120021 DOI: 10.1016/j.crohns.2013.09.010] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
148 Buchmann P, Mogg GA, Alexander-Williams J, Allan RN, Keighley MR. Relationship of proctitis and rectal capacity in Crohn's disease. Gut 1980;21:137-40. [PMID: 7380336 DOI: 10.1136/gut.21.2.137] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
149 Azzolini F, Pagnini C, Camellini L, Scarcelli A, Merighi A, Primerano AM, Bertani A, Antonioli A, Manenti F, Rigo GP. Proposal of a New Clinical Index Predictive of Endoscopic Severity in Ulcerative Colitis. Dig Dis Sci 2005;50:246-51. [DOI: 10.1007/s10620-005-1590-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
150 Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008; 14(36): 5584-5589 [PMID: 18810778 DOI: 10.3748/wjg.14.5584] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 97] [Article Influence: 6.6] [Reference Citation Analysis]
151 Cintolo M, Costantino G, Pallio S, Fries W. Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World J Gastrointest Pathophysiol 2016; 7(1): 1-16 [PMID: 26909224 DOI: 10.4291/wjgp.v7.i1.1] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
152 Ye CA, Gao YJ, Ge ZZ, Dai J, Li XB, Xue HB, Ran ZH, Zhao YJ. PillCam colon capsule endoscopy versus conventional colonoscopy for the detection of severity and extent of ulcerative colitis. J Dig Dis. 2013;14:117-124. [PMID: 23134295 DOI: 10.1111/1751-2980.12005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
153 Meenan J, Obradov DO, van Dullemen H, Tytgat GN, van Deventer SJ. Use of buffered formaldehyde in the enzymatic digestion of inflamed mucosa. J Clin Pathol 1996;49:177-9. [PMID: 8655691 DOI: 10.1136/jcp.49.2.177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
154 Pascu M, Roznowski AB, Müller HP, Adler A, Wiedenmann B, Dignass AU. Clinical relevance of transabdominal ultrasonography and magnetic resonance imaging in patients with inflammatory bowel disease of the terminal ileum and large bowel. Inflamm Bowel Dis. 2004;10:373-382. [PMID: 15475745 DOI: 10.1097/00054725-200407000-00008] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 4.3] [Reference Citation Analysis]
155 Stadnicki A, Pastucha E, Nowaczyk G, Mazurek U, Plewka D, Machnik G, Wilczok T, Colman RW. Immunolocalization and expression of kinin B1R and B2R receptors in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2005;289:G361-G366. [PMID: 15805101 DOI: 10.1152/ajpgi.00369.2004] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
156 Saitoh O, Kojima K, Sugi K, Matsuse R, Uchida K, Tabata K, Nakagawa K, Kayazawa M, Hirata I, Katsu K. Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease. Am J Gastroenterol. 1999;94:3513-3520. [PMID: 10606313 DOI: 10.1111/j.1572-0241.1999.01640.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 3.0] [Reference Citation Analysis]
157 Moum B, Ekbom A, Vatn MH, Elgjo K. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol. 1999;94:1564-1569. [PMID: 10364026 DOI: 10.1111/j.1572-0241.1999.01145.x] [Cited by in Crossref: 100] [Cited by in F6Publishing: 85] [Article Influence: 4.3] [Reference Citation Analysis]
158 Mosli MH, MacDonald JK, Bickston SJ, Behm BW, Tsoulis DJ, Cheng J, Khanna R, Feagan BG. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21:1151-1159. [PMID: 25844963 DOI: 10.1097/mib.0000000000000396] [Cited by in Crossref: 45] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
159 Kim JH, Cheon JH, Park Y, Lee HJ, Park SJ, Kim TI, Kim WH. Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission. Scand J Gastroenterol 2016;51:1069-74. [PMID: 26895215 DOI: 10.3109/00365521.2016.1150503] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
160 Misiewicz J, Lennard-jones J, Connell A, Baron J, Avery Jones F. CONTROLLED TRIAL OF SULPHASALAZINE IN MAINTENANCE THERAPY FOR ULCERATIVE COLITIS. The Lancet 1965;285:185-8. [DOI: 10.1016/s0140-6736(65)90972-4] [Cited by in Crossref: 250] [Cited by in F6Publishing: 1] [Article Influence: 4.4] [Reference Citation Analysis]
161 Freeman HJ. Medical management of ulcerative colitis with a specific focus on 5-aminosalicylates. Clin Med Insights Gastroenterol 2012;5:77-83. [PMID: 24833937 DOI: 10.4137/CGast.S8673] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
162 Miheller P, Mandel MD, Mullner K, Lakatos PL. Clinical aspects of mucosal healing in inflammatory bowel diseases: what is it and what is the real value for the everyday practice? Expert Rev Clin Immunol 2013;9:871-82. [PMID: 24070050 DOI: 10.1586/1744666X.2013.824675] [Reference Citation Analysis]
163 Paoluzi OA, Pica R, Marcheggiano A, Crispino P, Iacopini F, Iannoni C, Rivera M, Paoluzi P. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther. 2002;16:1751-1759. [PMID: 12269968 DOI: 10.1046/j.1365-2036.2002.01340.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 93] [Article Influence: 4.9] [Reference Citation Analysis]
164 Campieri M, Paoluzi P, D'albasio G, Brunetti G, Pera A, Barbara L. Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis: A multicenter comparative trial with 5-ASA enema. Digest Dis Sci 1993;38:1843-50. [DOI: 10.1007/bf01296108] [Cited by in Crossref: 50] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
165 Cushing KC, Tan W, Alpers DH, Deshpande V, Ananthakrishnan AN. Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission. Aliment Pharmacol Ther 2020;51:347-55. [PMID: 31696961 DOI: 10.1111/apt.15568] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
166 Rask-madsen J. THE RELATIONSHIP BETWEEN SODIUM FLUXES AND ELECTRICAL POTENTIALS ACROSS THE NORMAL AND INFLAMED HUMAN RECTAL WALL IN VIVO. Acta Medica Scandinavica 1973;194:311-7. [DOI: 10.1111/j.0954-6820.1973.tb19451.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
167 Osterman MT. Mucosal healing in inflammatory bowel disease. J Clin Gastroenterol. 2013;47:212-221. [PMID: 23340060 DOI: 10.1097/mcg.0b013e3182732ff5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 14] [Article Influence: 4.1] [Reference Citation Analysis]
168 Navratil E, Stettler C, Paul G, Vilotte J, Vissuzaine C, Mignon M, Potet F. Assessment of Dysplasia, Mucosal Mucins, p53 Protein Expression, and DNA Content in Ulcerative Colitis Patients with Colectomy and Ileorectal Anastomosis. Scandinavian Journal of Gastroenterology 2009;30:361-6. [DOI: 10.3109/00365529509093291] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
169 Lau A, Chande N, Ponich T, Gregor JC. Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2008;28:606-613. [PMID: 18564323 DOI: 10.1111/j.1365-2036.2008.03772.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
170 Bots S, Nylund K, Löwenberg M, Gecse K, Gilja OH, D'Haens G. Ultrasound for Assessing Disease Activity in IBD Patients: A Systematic Review of Activity Scores. J Crohns Colitis 2018;12:920-9. [PMID: 29684200 DOI: 10.1093/ecco-jcc/jjy048] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 8.5] [Reference Citation Analysis]
171 Meenan J, Spaans J, Grool TA, Lammers K, Pals S, Tytgat GN, van Deventer SJ. Variation in gut-homing CD27-negative lymphocytes in inflammatory colon disease. Scand J Immunol 1998;48:318-23. [PMID: 9743220 DOI: 10.1046/j.1365-3083.1998.00387.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
172 Martín de Carpi J, Vilar P, Prieto G, García Novo MD, Ribes C, Varea V. Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study. J Pediatr Gastroenterol Nutr. 2008;46:386-391. [PMID: 18367949 DOI: 10.1097/mpg.0b013e31815604e5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
173 Pérez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis. Drugs 2021;81:985-1002. [PMID: 33983615 DOI: 10.1007/s40265-021-01528-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
174 d'Albasio G, Paoluzi P, Campieri M, Bianchi Porro G, Pera A, Prantera C, Sturniolo GC, Miglioli M. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group. Am J Gastroenterol. 1998;93:799-803. [PMID: 9625131 DOI: 10.1111/j.1572-0241.1998.228_a.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 1.8] [Reference Citation Analysis]
175 Cheon JH, Kim WH. Recent advances of endoscopy in inflammatory bowel diseases. Gut Liver. 2007;1:118-125. [PMID: 20485627 DOI: 10.5009/gnl.2007.1.2.118] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
176 Mcneil NI. The effect of luminal pH on large intestinal absorption in ulcerative proctocolitis. Diseases of the Colon & Rectum 1986;29:814-6. [DOI: 10.1007/bf02555352] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
177 Bossa F, Latiano A, Rossi L, Magnani M, Palmieri O, Dallapiccola B, Serafini S, Damonte G, De Santo E, Andriulli A. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am J Gastroenterol. 2008;103:2509-2516. [PMID: 18721243 DOI: 10.1111/j.1572-0241.2008.02103.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
178 Vilela EG, Torres HODG, Martins FP, Ferrari MLA, Andrade MM, Cunha ASD. Evaluation of inflammatory activity in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2012; 18(9): 872-881 [PMID: 22408345 DOI: 10.3748/wjg.v18.i9.872] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
179 Kawashima K, Ishihara S, Yuki T, Fukuba N, Oshima N, Kazumori H, Sonoyama H, Yamashita N, Tada Y, Kusunoki R, Oka A, Mishima Y, Moriyama I, Kinoshita Y. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol 2016;16:47. [PMID: 27071448 DOI: 10.1186/s12876-016-0462-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
180 Katsanos KH, Briasoulis E, Tsekeris P, Batistatou A, Bai M, Tolis C, Capizzello A, Panelos I, Karavasilis V, Christodoulou D. Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis. J Exp Clin Cancer Res. 2010;29:68. [PMID: 20537164 DOI: 10.1186/1756-9966-29-68] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
181 Levenstein S, Prantera C, Varvo V, Scribano ML, Andreoli A, Luzi C, Arcà M, Berto E, Milite G, Marcheggiano A. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol 2000;95:1213-20. [PMID: 10811330 DOI: 10.1111/j.1572-0241.2000.02012.x] [Cited by in Crossref: 280] [Cited by in F6Publishing: 264] [Article Influence: 12.7] [Reference Citation Analysis]
182 Sehgal R, Koltun WA. Scoring systems in inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2014;4:513-21. [DOI: 10.1586/egh.10.40] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
183 Al-Mofarreh MA, Al-Mofleh IA. Emerging inflammatory bowel disease in saudi outpatients: a report of 693 cases. Saudi J Gastroenterol. 2013;19:16-22. [PMID: 23319033 DOI: 10.4103/1319-3767.105915] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
184 Kmiot WA, Hesslewood SR, Smith N, Thompson H, Harding L, Keighley MR. Evaluation of the inflammatory infiltrate in pouchitis with 111In-labeled granulocytes. Gastroenterology 1993;104:981-8. [DOI: 10.1016/0016-5085(93)90264-d] [Cited by in Crossref: 43] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
185 Sharma MP, Duphare HV, Dasarathy S. A prospective randomized double blind trial comparing prednisolone and 4-aminosalicylic acid enemas in acute distal ulcerative colitis. J Gastroenterol Hepatol 1992;7:173-7. [DOI: 10.1111/j.1440-1746.1992.tb00957.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
186 Timmer A, Patton PH, Chande N, McDonald JW, MacDonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2016;:CD000478. [PMID: 27192092 DOI: 10.1002/14651858.CD000478.pub4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
187 Stadnicki A, Machnik G, Klimacka-nawrot E, Wolanska-karut A, Labuzek K. Transforming growth factor-β1 and its receptors in patients with ulcerative colitis. International Immunopharmacology 2009;9:761-6. [DOI: 10.1016/j.intimp.2009.02.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
188 Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut 2003;52:1587-90. [PMID: 14570727 DOI: 10.1136/gut.52.11.1587] [Cited by in Crossref: 161] [Cited by in F6Publishing: 144] [Article Influence: 8.9] [Reference Citation Analysis]
189 Kjeldsen J, De Muckadell OBS. Assessment of Disease Severity and Activity in Inflammatory Bowel Disease. Scandinavian Journal of Gastroenterology 2009;28:1-9. [DOI: 10.3109/00365529309096037] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 3.6] [Reference Citation Analysis]
190 Hawthorne AB, Daneshmend TK, Hawkey CJ, Belluzzi A, Everitt SJ, Holmes GK, Malkinson C, Shaheen MZ, Willars JE. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut. 1992;33:922-928. [PMID: 1353742 DOI: 10.1136/gut.33.7.922] [Cited by in Crossref: 227] [Cited by in F6Publishing: 179] [Article Influence: 7.6] [Reference Citation Analysis]
191 Dick AP, Grayson MJ, Carpenter RG, Petrie A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut. 1964;5:437-442. [PMID: 14218553 DOI: 10.1136/gut.5.5.437] [Cited by in Crossref: 186] [Cited by in F6Publishing: 173] [Article Influence: 7.2] [Reference Citation Analysis]
192 Rameshshanker R, Arebi N. Endoscopy in inflammatory bowel disease when and why. World J Gastrointest Endosc 2012; 4(6): 201-211 [PMID: 22720120 DOI: 10.4253/wjge.v4.i6.201] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
193 Kanazawa M, Tominaga K, Yamamiya A, Tanaka T, Watanabe S, Sugaya T, Abe K, Kanamori A, Arisaka T, Hoshi K, Iijima M, Goda K, Haruyama Y, Irisawa A. Analysis of Endoscopic Evaluation Reliability for Ulcerative Colitis in Histological Remission. Healthcare (Basel) 2021;9:1405. [PMID: 34828451 DOI: 10.3390/healthcare9111405] [Reference Citation Analysis]
194 Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;:CD000478. [PMID: 17253451 DOI: 10.1002/14651858.CD000478.pub2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 33] [Article Influence: 4.2] [Reference Citation Analysis]
195 Jergens AE, Willard MD, Allenspach K. Maximizing the diagnostic utility of endoscopic biopsy in dogs and cats with gastrointestinal disease. The Veterinary Journal 2016;214:50-60. [DOI: 10.1016/j.tvjl.2016.04.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
196 McNeil NI, Ling KL, Wager J. Mucosal surface pH of the large intestine of the rat and of normal and inflamed large intestine in man. Gut 1987;28:707-13. [PMID: 3623217 DOI: 10.1136/gut.28.6.707] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 1.0] [Reference Citation Analysis]
197 Tack J. Review article: the role of bile and pepsin in the pathophysiology and treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;24 Suppl 2:10-16. [PMID: 16939428 DOI: 10.1111/j.1365-2036.2006.03070.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
198 Ahmad H, Berzin TM, Yu HJ, Huang CS, Mishkin DS. Central endoscopy reads in inflammatory bowel disease clinical trials: The role of the imaging core lab. Gastroenterol Rep (Oxf) 2014;2:201-6. [PMID: 24994835 DOI: 10.1093/gastro/gou033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
199 Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991;32:174-178. [PMID: 1864537 DOI: 10.1136/gut.32.2.174] [Cited by in Crossref: 344] [Cited by in F6Publishing: 317] [Article Influence: 11.1] [Reference Citation Analysis]
200 Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol. 2005;3:11-24. [PMID: 15645399 DOI: 10.1016/s1542-3565(04)00441-0] [Cited by in Crossref: 93] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
201 McCarthy DA, Rampton DS, Liu YC. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol. 1991;86:489-493. [PMID: 1684141 DOI: 10.1111/j.1365-2249.1991.tb02958.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 89] [Article Influence: 2.7] [Reference Citation Analysis]
202 Ruddell WS, Blendis LM, Lovell D. Rectal potential difference and histology in Crohn's disease. Gut 1977;18:284-9. [PMID: 863288 DOI: 10.1136/gut.18.4.284] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
203 Mahida YR, Gallagher A, Kurlak L, Hawkey CJ. Plasma and tissue interleukin-2 receptor levels in inflammatory bowel disease. Clin Exp Immunol. 1990;82:75-80. [PMID: 2208797 DOI: 10.1111/j.1365-2249.1990.tb05406.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 1.5] [Reference Citation Analysis]
204 Misiewicz JJ, Connell AM, Lennard-jones JE, Jones FA. Comparison of Oral and Rectal Steroids in the Treatment of Proctocolitis. Proceedings of the Royal Society of Medicine 2016;57:561-2. [DOI: 10.1177/003591576405700712] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
205 Manguso F, Bennato R, Lombardi G, Riccio E, Costantino G, Fries W. Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0166455. [PMID: 27846307 DOI: 10.1371/journal.pone.0166455] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
206 Clark M, Colombel J, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21–23, 2006. Gastroenterology 2007;133:312-39. [DOI: 10.1053/j.gastro.2007.05.006] [Cited by in Crossref: 157] [Cited by in F6Publishing: 145] [Article Influence: 10.5] [Reference Citation Analysis]
207 Riis P, Valdorf-Hansen F, Anthonisen P. Cytology of colonic mucosal secretions from patients with non-specific haemorrhagic proctocolitis in complete clinical remission. Br Med J 1966;1:712-4. [PMID: 5295549 DOI: 10.1136/bmj.1.5489.712] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
208 Carty E, De Brabander M, Feakins RM, Rampton DS. Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut. 2000;46:487-492. [PMID: 10716677 DOI: 10.1136/gut.46.4.487] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 3.2] [Reference Citation Analysis]
209 Nakase H, Hirano T, Wagatsuma K, Ichimiya T, Yamakawa T, Yokoyama Y, Hayashi Y, Hirayama D, Kazama T, Yoshii S, Yamano HO. Artificial intelligence-assisted endoscopy changes the definition of mucosal healing in ulcerative colitis. Dig Endosc. 2020;. [PMID: 32909283 DOI: 10.1111/den.13825] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
210 Forbes A, Britton TC, House IM, Gazzard BG. Safety and efficacy of acetarsol suppositories in unresponsive proctitis. Aliment Pharmacol Ther. 1989;3:553-556. [PMID: 2518869 DOI: 10.1111/j.1365-2036.1989.tb00247.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 0.8] [Reference Citation Analysis]
211 Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;11:CD004118. [PMID: 23152224 DOI: 10.1002/14651858.CD004118.pub2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
212 Campieri M, Adamo S, Valpiani D, D'Arienzo A, D'Albasio G, Pitzalis M, Cesari P, Casetti T, Castiglione GN, Rizzello F, Manguso F, Varoli G, Gionchetti P. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther. 2003;17:1471-1480. [PMID: 12823149 DOI: 10.1046/j.1365-2036.2003.01609.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 69] [Article Influence: 4.2] [Reference Citation Analysis]
213 Paoluzi OA, Iacopini F, Pica R, Crispino P, Marcheggiano A, Consolazio A, Rivera M, Paoluzi P. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther. 2005;21:1111-1119. [PMID: 15854173 DOI: 10.1111/j.1365-2036.2005.02458.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 3.5] [Reference Citation Analysis]
214 Mohammed Vashist N, Samaan M, Mosli MH, Parker CE, MacDonald JK, Nelson SA, Zou GY, Feagan BG, Khanna R, Jairath V. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev 2018;1:CD011450. [PMID: 29338066 DOI: 10.1002/14651858.CD011450.pub2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
215 Mahadevan U, Tremaine WJ, Johnson T, Pike GM, Mays DC, Lipsky JJ, Sandborn WJ. Intravenous Azathioprine in Severe Ulcerative Colitis: A Pilot Study. American Journal of Gastroenterology 2000;95:3463-8. [DOI: 10.1111/j.1572-0241.2000.03362.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
216 Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D, Taylor SA, Rimola J, Rieder F, Limdi JK, Laghi A, Krustiņš E, Kotze PG, Kopylov U, Katsanos K, Halligan S, Gordon H, González Lama Y, Ellul P, Eliakim R, Castiglione F, Burisch J, Borralho Nunes P, Bettenworth D, Baumgart DC, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis 2019;13:273-84. [PMID: 30137278 DOI: 10.1093/ecco-jcc/jjy114] [Cited by in Crossref: 92] [Cited by in F6Publishing: 75] [Article Influence: 30.7] [Reference Citation Analysis]
217 O'morain C, Tobin A, Leen E, Suzuki Y, O'riordan T. Criteria of Case Definition in Crohn's Disease and Ulcerative Colitis. Scandinavian Journal of Gastroenterology 2009;24:7-11. [DOI: 10.3109/00365528909091340] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
218 Wheatcroft A, Hollander A, Croucher L, Jones A, Taylor C, Evans G. Evidence of in situ stability of the type IV collagen triple helix in human inflammatory bowel disease using a denaturation specific epitope antibody. Matrix Biology 1999;18:361-72. [DOI: 10.1016/s0945-053x(99)00028-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
219 Philipsen EK, Bondesen S, Andersen J, Larsen S. Serum immunoglobulin G subclasses in patients with ulcerative colitis and Crohn's disease of different disease activities. Scand J Gastroenterol. 1995;30:50-53. [PMID: 7701250 DOI: 10.3109/00365529509093235] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
220 Osada T, Ohkusa T, Yokoyama T, Shibuya T, Sakamoto N, Beppu K, Nagahara A, Otaka M, Ogihara T, Watanabe S. Comparison of several activity indices for the evaluation of endoscopic activity in UC: inter- and intraobserver consistency. Inflamm Bowel Dis. 2010;16:192-197. [PMID: 19575359 DOI: 10.1002/ibd.21000] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
221 Rizzello F, Gionchetti P, Venturi A, Amadini C, Romagnoli R, Campieri M. Review article: monitoring activity in ulcerative colitis. Aliment Pharmacol Ther 2002;16 Suppl 4:3-6. [PMID: 12047252 DOI: 10.1046/j.1365-2036.16.s4.1.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
222 Brochard C, Siproudhis L, Ropert A, Mallak A, Bretagne JF, Bouguen G. Anorectal dysfunction in patients with ulcerative colitis: impaired adaptation or enhanced perception? Neurogastroenterol Motil. 2015;27:1032-1037. [PMID: 25940976 DOI: 10.1111/nmo.12580] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
223 Boal Carvalho P, Cotter J. Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. Drugs. 2017;77:159-173. [PMID: 28078646 DOI: 10.1007/s40265-016-0676-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
224 Buckell NA, Gould SR, Day DW, Lennard-Jones JE, Edwards AM. Controlled trial of disodium cromoglycate in chronic persistent ulcerative colitis. Gut 1978;19:1140-3. [PMID: 105970 DOI: 10.1136/gut.19.12.1140] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 1.0] [Reference Citation Analysis]
225 Lee DA, Taylor M, James VH, Walker G. Rectally administered prednisolone--evidence for a predominantly local action. Gut 1980;21:215-8. [PMID: 7399322 DOI: 10.1136/gut.21.3.215] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 0.9] [Reference Citation Analysis]
226 Sasaki Y, Fukuda S, Mikami T, Hada R. ENDOSCOPIC QUANTIFICATION OF MUCOSAL SURFACE ROUGHNESS FOR GRADING SEVERITY OF ULCERATIVE COLITIS. Dig Endosc 2008;20:67-72. [DOI: 10.1111/j.1443-1661.2008.00778.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
227 Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis. 2011;5:115-121. [PMID: 21453880 DOI: 10.1016/j.crohns.2010.11.004] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
228 Hjortswang H, Strom M, Almeida RT, Almer S. Evaluation of the RFIPC, a Disease-Specific Health-Related Quality of Life Questionnaire, in Swedish Patients with Ulcerative Colitis. Scandinavian Journal of Gastroenterology 2009;32:1235-40. [DOI: 10.3109/00365529709028153] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
229 Carty E, Rampton DS. Evaluation of new therapies for inflammatory bowel disease. Br J Clin Pharmacol 2003;56:351-61. [PMID: 12968979 DOI: 10.1046/j.1365-2125.2003.01965.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
230 Li FX, Sutherland LR. Assessing disease activity and disease activity indices for inflammatory bowel disease. Curr Gastroenterol Rep 2002;4:490-6. [DOI: 10.1007/s11894-002-0025-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
231 Modigliani R, Mary JY; Groupe d'etudes therapeutiques des affections inflammatoires du tube digestif (getaid). Reproducibility of colonoscopic findings in Crohn's disease: A prospective multicenter study of interobserver variation. Digest Dis Sci 1987;32:1370-9. [DOI: 10.1007/bf01296663] [Cited by in Crossref: 55] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
232 Saigusa K, Matsuoka K, Sugimoto S, Arai M, Kiyohara H, Takeshita K, Mizuno S, Mori K, Nanki K, Takeshita T, Nakazato Y, Yajima T, Naganuma M, Hisamatsu T, Ogata H, Iwao Y, Kanai T. Ulcerative colitis endoscopic index of severity is associated with long‐term prognosis in ulcerative colitis patients treated with infliximab. Digestive Endoscopy 2016;28:665-70. [DOI: 10.1111/den.12655] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
233 Langmead L, Dawson C, Hawkins C, Banna N, Loo S, Rampton DS. Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study. Aliment Pharmacol Ther. 2002;16:197-205. [PMID: 11860402 DOI: 10.1046/j.1365-2036.2002.01157.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 3.1] [Reference Citation Analysis]
234 Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43:29-32. [PMID: 9771402 DOI: 10.1136/gut.43.1.29] [Cited by in Crossref: 738] [Cited by in F6Publishing: 733] [Article Influence: 30.8] [Reference Citation Analysis]
235 Dimitroulia E, Spanakis N, Konstantinidou AE, Legakis NJ, Tsakris A. Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:879-884. [PMID: 16954807 DOI: 10.1097/01.mib.0000231576.11678.57] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 5.3] [Reference Citation Analysis]
236 Walsh A, Palmer R, Travis S. Mucosal Healing As a Target of Therapy for Colonic Inflammatory Bowel Disease and Methods to Score Disease Activity. Gastrointestinal Endoscopy Clinics of North America 2014;24:367-78. [DOI: 10.1016/j.giec.2014.03.005] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 8.6] [Reference Citation Analysis]
237 Rampton DS, McNeil NI, Sarner M. Analgesic ingestion and other factors preceding relapse in ulcerative colitis. Gut 1983;24:187-9. [PMID: 6826100 DOI: 10.1136/gut.24.3.187] [Cited by in Crossref: 118] [Cited by in F6Publishing: 97] [Article Influence: 3.0] [Reference Citation Analysis]
238 Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851. [PMID: 30837080 DOI: 10.1016/j.disamonth.2019.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 16.7] [Reference Citation Analysis]
239 Ruddell WS, Dickinson RJ, Dixon MF, Axon AT. Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparison of hydrocortisone enemas and rectal hydrocortisone foam. Gut. 1980;21:885-889. [PMID: 7002739 DOI: 10.1136/gut.21.10.885] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 1.4] [Reference Citation Analysis]
240 Yamamoto-furusho J, Bosques-padilla F, de-Paula J, Galiano M, Ibañez P, Juliao F, Kotze P, Rocha J, Steinwurz F, Veitia G, Zaltman C. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México 2017;82:46-84. [DOI: 10.1016/j.rgmx.2016.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
241 Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? J Crohns Colitis. 2014;8:1582-1597. [PMID: 25267173 DOI: 10.1016/j.crohns.2014.08.011] [Cited by in Crossref: 162] [Cited by in F6Publishing: 146] [Article Influence: 20.3] [Reference Citation Analysis]
242 Tontini GE, Bisschops R, Neumann H. Endoscopic scoring systems for inflammatory bowel disease: pros and cons. Expert Rev Gastroenterol Hepatol. 2014;8:543-554. [PMID: 24650249 DOI: 10.1586/17474124.2014.899899] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
243 Mawdsley JE, Macey MG, Feakins RM, Langmead L, Rampton DS. The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Gastroenterology. 2006;131:410-419. [PMID: 16890594 DOI: 10.1053/j.gastro.2006.05.017] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 5.3] [Reference Citation Analysis]
244 Fraser GM, Findlay JM. The double contrast enema in ulcerative and Crohn's colitis. Clin Radiol. 1976;27:103-112. [PMID: 1261191 DOI: 10.1016/s0009-9260(76)80030-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
245 Mawdsley JE, Lindsay J, Rampton D. Synbiotic therapy for ulcerative colitis. Gut 2005;54:1346. [PMID: 16099808 DOI: 10.1136/gut.2005.070599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
246 Dunckley P, Jewell D. Management of acute severe colitis. Best Practice & Research Clinical Gastroenterology 2003;17:89-103. [DOI: 10.1053/bega.2002.0343] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
247 Stadnicki A, Mazurek U, Gonciarz M, Plewka D, Nowaczyk G, Orchel J, Pastucha E, Plewka A, Wilczok T, Colman RW. Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease. Dig Dis Sci 2003;48:615-23. [PMID: 12757180 DOI: 10.1023/a:1022569623350] [Cited by in Crossref: 19] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
248 Ellrichmann M, Wietzke-Braun P, Dhar S, Nikolaus S, Arlt A, Bethge J, Kuehbacher T, Wintermeyer L, Balschun K, Klapper W. Endoscopic ultrasound of the colon for the differentiation of Crohn’s disease and ulcerative colitis in comparison with healthy controls. Aliment Pharmacol Ther. 2014;39:823-833. [PMID: 24612000 DOI: 10.1111/apt.12671] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
249 Moran CP, Neary B, Doherty GA. Endoscopic evaluation in diagnosis and management of inflammatory bowel disease. World J Gastrointest Endosc 2016; 8(20): 723-732 [PMID: 28042386 DOI: 10.4253/wjge.v8.i20.723] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
250 Rampton DS, Sladen GE. Prostaglandin synthesis inhibitors in ulcerative colitis: flurbiprofen compared with conventional treatment. Prostaglandins 1981;21:417-25. [PMID: 6112777 DOI: 10.1016/0090-6980(81)90087-3] [Cited by in Crossref: 101] [Cited by in F6Publishing: 85] [Article Influence: 2.5] [Reference Citation Analysis]
251 Angus P, Snook JA, Reid M, Jewell DP. Oral fluticasone propionate in active distal ulcerative colitis. Gut 1992;33:711-4. [PMID: 1612492 DOI: 10.1136/gut.33.5.711] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 1.3] [Reference Citation Analysis]
252 Rampton DS, Sladen GE, Youlten LJ. Rectal mucosal prostaglandin E2 release and its relation to disease activity, electrical potential difference, and treatment in ulcerative colitis. Gut 1980;21:591-6. [PMID: 7429322 DOI: 10.1136/gut.21.7.591] [Cited by in Crossref: 88] [Cited by in F6Publishing: 97] [Article Influence: 2.1] [Reference Citation Analysis]
253 Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: A Pouchitis Disease Activity Index. Mayo Clin Proc. 1994;69:409-415. [PMID: 8170189 DOI: 10.1016/s0025-6196(12)61634-6] [Cited by in Crossref: 506] [Cited by in F6Publishing: 111] [Article Influence: 18.1] [Reference Citation Analysis]
254 Stadnicki A, Mazurek U, Plewka D, Wilczok T. Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease. Int Immunopharmacol 2003;3:939-44. [PMID: 12810351 DOI: 10.1016/S1567-5769(03)00054-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
255 Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53. [PMID: 15972298 DOI: 10.1136/gut.2005.068809] [Cited by in Crossref: 354] [Cited by in F6Publishing: 318] [Article Influence: 20.8] [Reference Citation Analysis]
256 Almers S, Granerus G, Franz�n L, Str�m M. Technetium-99m scintigraphy: more accurate assessment of ulcerative colitis with exametazime-labelled leucocytes than with antigranulocyte antibodies. Eur J Nucl Med 1996;23:247-55. [DOI: 10.1007/bf00837622] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
257 Khanna R, Ma C, Jairath V, Vande Casteele N, Zou G, Feagan BG. Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31674-8. [PMID: 33338657 DOI: 10.1016/j.cgh.2020.12.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
258 Gabrielsson N, Granqvist S, Sundelin P, Thorgeirsson T. Extent of inflammatory lesions in ulcerative colitis assessed by radiology, colonoscopy, and endoscopic biopsies. Gastrointest Radiol 1979;4:395-400. [DOI: 10.1007/bf01887564] [Cited by in Crossref: 30] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
259 de Lange T, Svensen A, Larsen S, Aabakken L. The functionality and reliability of an Internet interface for assessments of endoscopic still images and video clips: distributed research in gastroenterology. Gastrointestinal Endoscopy 2006;63:445-52. [DOI: 10.1016/j.gie.2005.11.053] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
260 Ventham NT, Kalla R, Kennedy NA, Satsangi J, Arnott ID. Predicting outcomes in acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2015;9:405-415. [PMID: 25494666 DOI: 10.1586/17474124.2015.992880] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
261 Kucharski M, Karczewski J, Mańkowska-wierzbicka D, Karmelita-katulska K, Grzymisławski M, Kaczmarek E, Iwanik K, Rzymski P, Swora-cwynar E, Linke K, Dobrowolska A. Applicability of endoscopic indices in the determination of disease activity in patients with ulcerative colitis: . European Journal of Gastroenterology & Hepatology 2016;28:722-30. [DOI: 10.1097/meg.0000000000000601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
262 Mohammed N, Subramanian V. Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes? World J Gastroenterol 2016; 22(42): 9324-9332 [PMID: 27895420 DOI: 10.3748/wjg.v22.i42.9324] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
263 Hu TQ, Shao ZY, Wang Y. Clinical efficacy of Qingchang Huashi recipe combined with mesalazine in treatment of patients with active ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2016; 24(36): 4824-4829 [DOI: 10.11569/wcjd.v24.i36.4824] [Reference Citation Analysis]
264 Langmead L, Makins RJ, Rampton DS. Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro. Aliment Pharmacol Ther. 2004;19:521-527. [PMID: 14987320 DOI: 10.1111/j.1365-2036.2004.01874.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 100] [Article Influence: 6.3] [Reference Citation Analysis]
265 Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S, Warren BF, Travis SP. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65:408-414. [PMID: 25986946 DOI: 10.1136/gutjnl-2015-309598] [Cited by in Crossref: 190] [Cited by in F6Publishing: 173] [Article Influence: 27.1] [Reference Citation Analysis]
266 Agarwal A, Kedia S, Jain S, Gupta V, Bopanna S, Yadav DP, Goyal S, Mouli VP, Dhingra R, Makharia G, Ahuja V. High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India. Intest Res 2018;16:588-98. [PMID: 30301331 DOI: 10.5217/ir.2018.00023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
267 Khanna R, Feagan BG. Through the Looking Glass: A Journey Toward Optimal Endoscopic Assessment of Disease Activity in Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2013;11:55-6. [DOI: 10.1016/j.cgh.2012.09.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
268 Mowat NAG, Douglas AS, Brunt PW, Mcintosh JAR, King PC, Boddy K. Epsilon-Aminocaproic acid therapy in ulcerative colitis. Digest Dis Sci 1973;18:959-65. [DOI: 10.1007/bf01072440] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
269 Bianchi V, Maconi G, Ardizzone S, Colombo E, Ferrara E, Russo A, Tenchini ML, Porro GB. Association of NOD2/CARD15 mutations on Crohn's disease phenotype in an Italian population. Eur J Gastroenterol Hepatol. 2007;19:217-223. [PMID: 17301648 DOI: 10.1097/01.meg.0000250590.84102.12] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
270 Almer S, Franzén L, Olaison G, Smedh K, Ström M. Increased absorption of polyethylene glycol 600 deposited in the colon in active ulcerative colitis. Gut. 1993;34:509-513. [PMID: 8491399 DOI: 10.1136/gut.34.4.509] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 0.9] [Reference Citation Analysis]
271 Dearling JLJ, Daka A, Veiga N, Peer D, Packard AB. Colitis ImmunoPET: Defining Target Cell Populations and Optimizing Pharmacokinetics. Inflammatory Bowel Diseases 2016;22:529-38. [DOI: 10.1097/mib.0000000000000677] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
272 Jensen SR, Fink LN, Nielsen OH, Brynskov J, Brix S. Ex vivo intestinal adhesion of Escherichia coli LF82 in Crohn’s disease. Microb Pathog. 2011;51:426-431. [PMID: 21911052 DOI: 10.1016/j.micpath.2011.08.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
273 Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;CD000478. [PMID: 22972046 DOI: 10.1002/14651858.cd000478.pub3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
274 Goodhand JR, Wahed M, Mawdsley JE, Farmer AD, Aziz Q, Rampton DS. Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm Bowel Dis. 2012;18:2301-2309. [PMID: 22359369 DOI: 10.1002/ibd.22916] [Cited by in Crossref: 127] [Cited by in F6Publishing: 112] [Article Influence: 12.7] [Reference Citation Analysis]
275 Armuzzi A, Van Assche G, Reinisch W, de Chambrun GP, Griffiths A, Sladek M, Preiss JC, Lukas M, D'haens G. Results of the 2nd scientific workshop of the ECCO (IV): Therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. Journal of Crohn's and Colitis 2012;6:492-502. [DOI: 10.1016/j.crohns.2011.12.016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
276 Hirai F, Matsui T, Aoyagi K, Inoue N, Hibi T, Oshitani N, Fujii H, Kobayashi K, Suzuki Y, Tanaka S. Validity of activity indices in ulcerative colitis: comparison of clinical and endoscopic indices. Dig Endosc. 2010;22:39-44. [PMID: 20078663 DOI: 10.1111/j.1443-1661.2009.00916.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
277 Gottlieb K, Daperno M, Usiskin K, Sands BE, Ahmad H, Howden CW, Karnes W, Oh YS, Modesto I, Marano C, Stidham RW, Reinisch W. Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments. Gut 2021;70:418-26. [PMID: 32699100 DOI: 10.1136/gutjnl-2020-320690] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
278 Soweid AM, Chak A, Katz JA, Sivak MV. Catheter probe–assisted endoluminal US in inflammatory bowel disease. Gastrointestinal Endoscopy 1999;50:41-6. [DOI: 10.1016/s0016-5107(99)70342-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
279 Niu JK, Miao YL. Endoscopic diagnosis and treatment of ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2011; 19(20): 2153-2159 [DOI: 10.11569/wcjd.v19.i20.2153] [Reference Citation Analysis]
280 Workum P, Delbono EA, Holford SK, Murphy RL. Observer Agreement, Chest Auscultation, and Crackles in Asbestos-Exposed Workers. Chest 1986;89:27-9. [DOI: 10.1378/chest.89.1.27] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
281 Conn HO, Elkington SG. Is Hepatic Scanning Overrated? Gastroenterology 1968;54:135-40. [DOI: 10.1016/s0016-5085(68)80052-6] [Cited by in Crossref: 28] [Article Influence: 0.5] [Reference Citation Analysis]
282 Almy TP, Plaut AG. Ulcerative Colitis: A Report of Progress, Based Upon the Recent Literature. Gastroenterology 1965;49:295-314. [DOI: 10.1016/s0016-5085(19)34543-3] [Cited by in Crossref: 10] [Article Influence: 0.2] [Reference Citation Analysis]
283 de Lange T, Larsen S, Aabakken L. Image documentation of endoscopic findings in ulcerative colitis: photographs or video clips? Gastrointest Endosc 2005;61:715-20. [PMID: 15855977 DOI: 10.1016/s0016-5107(05)00337-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
284 Yoon JY, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci 2014;59:829-37. [PMID: 24352705 DOI: 10.1007/s10620-013-2907-3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
285 Dearling JLJ, Packard AB. PET-Radioimmunodetection of Integrins: Imaging Acute Colitis Using a 64Cu-Labeled Anti-β7 Integrin Antibody. In: Shimaoka M, editor. Integrin and Cell Adhesion Molecules. Totowa: Humana Press; 2012. pp. 487-96. [DOI: 10.1007/978-1-61779-166-6_28] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
286 Oh YS, Chung WC, Hwang SS, Lee KM, Paik CN, Cho YS, Lee BI, Choi GY. [The usefulness of Doppler sonography in the assessment of disease activity of ulcerative colitis]. Korean J Gastroenterol 2010;56:346-52. [PMID: 21173557 DOI: 10.4166/kjg.2010.56.6.346] [Reference Citation Analysis]
287 Scarpa M, Behboo R, Angriman I, Termini B, Barollo M, Ruffolo C, Polese L, D’incà R, Sturniolo GC, D’amico DF. The Role of Costimulatory Molecules CD80 and CD86 and IFNγ in the Pathogenesis of Ulcerative Colitis. Dig Dis Sci 2004;49:1738-44. [DOI: 10.1007/s10620-004-9562-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
288 Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, Feakins R, Fléjou JF, Herfarth H, Hommes DW. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis. 2008;2:1-23. [PMID: 21172194 DOI: 10.1016/j.crohns.2007.11.001] [Cited by in Crossref: 353] [Cited by in F6Publishing: 324] [Article Influence: 25.2] [Reference Citation Analysis]
289 Tang R, Yang G, Zhang S, Wu C, Chen M. Opposite Effects of Interferon Regulatory Factor 1 and Osteopontin on the Apoptosis of Epithelial Cells Induced by TNF-α in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2014;20:1950-61. [DOI: 10.1097/mib.0000000000000192] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
290 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
291 Srivastava S, Kedia S, Kumar S, Pratap Mouli V, Dhingra R, Sachdev V, Tiwari V, Kurrey L, Pradhan R, Ahuja V. Serum human trefoil factor 3 is a biomarker for mucosal healing in ulcerative colitis patients with minimal disease activity. J Crohns Colitis. 2015;9:575-579. [PMID: 25964429 DOI: 10.1093/ecco-jcc/jjv075] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
292 Kudo T, Matsumoto T, Esaki M, Yao T, Iida M. Mucosal vascular pattern in ulcerative colitis: observations using narrow band imaging colonoscopy with special reference to histologic inflammation. Int J Colorectal Dis. 2009;24:495-501. [PMID: 19145441 DOI: 10.1007/s00384-008-0631-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
293 Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment Pharmacol Ther. 2007;26:21-29. [PMID: 17555418 DOI: 10.1111/j.1365-2036.2007.03349.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
294 Restellini S, Chao CY, Martel M, Barkun A, Kherad O, Seidman E, Wild G, Bitton A, Afif W, Bessissow T, Lakatos PL. Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis: A Systematic Review. Clin Gastroenterol Hepatol 2019; 17: 1265-1275. e8. [PMID: 30583048 DOI: 10.1016/j.cgh.2018.12.021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
295 Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015; 148:37-51.e1. [PMID: 25127678 DOI: 10.1053/j.gastro.2014.08.003] [Cited by in Crossref: 142] [Cited by in F6Publishing: 124] [Article Influence: 17.8] [Reference Citation Analysis]
296 Ito H, Iida M, Matsumoto T, Suzuki Y, Aida Y, Yoshida T, Takano Y, Hibi T. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis 2010;16:1575-82. [PMID: 20049949 DOI: 10.1002/ibd.21194] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
297 Zittan E, Steinhart AH, Aran H, Milgrom R, Gralnek IM, Zelber-Sagi S, Silverberg MS. The Toronto Ibd Global Endoscopic Reporting (Tiger) Score: A Single, Easy To Use Endoscopic Score For Both Crohn's Disease And Ulcerative Colitis Patients. J Crohns Colitis 2021:jjab122. [PMID: 34272937 DOI: 10.1093/ecco-jcc/jjab122] [Reference Citation Analysis]
298 Rizzello F, Gionchetti P, Venturi A, Campieri M. Review article: medical treatment of severe ulcerative colitis. Aliment Pharmacol Ther 2003;17 Suppl 2:7-10. [PMID: 12786606 DOI: 10.1046/j.1365-2036.17.s2.18.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
299 Rizzello F, Gionchetti P, D’Arienzo A, Manguso F, Di Matteo G, Annese V, Valpiani D, Casetti T, Adamo S, Prada A. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2002;16:1109-1116. [PMID: 12030952 DOI: 10.1046/j.1365-2036.2002.01298.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 4.9] [Reference Citation Analysis]
300 Rizzello F, Campieri M, Tambasco R, Straforini G, Brugnera R, Poggioli G, Gionchetti P. Medical treatment and management of severe ulcerative colitis. Dig Liver Dis 2008;40 Suppl 2:S280-4. [PMID: 18599001 DOI: 10.1016/S1590-8658(08)60538-1] [Reference Citation Analysis]
301 Cooney RM, Warren BF, Altman DG, Abreu MT, Travis SP. Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials 2007;8:17. [PMID: 17592647 DOI: 10.1186/1745-6215-8-17] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 5.3] [Reference Citation Analysis]
302 Jones-Hall YL, Grisham MB. Immunopathological characterization of selected mouse models of inflammatory bowel disease: Comparison to human disease. Pathophysiology. 2014;21:267-288. [PMID: 24935242 DOI: 10.1016/j.pathophys.2014.05.002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
303 Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;CD005112. [PMID: 16856078 DOI: 10.1002/14651858.cd005112.pub2] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
304 Hisabe T, Matsui T, Miyaoka M, Ninomiya K, Ishihara H, Nagahama T, Takaki Y, Hirai F, Ikeda K, Iwashita A, Higashi D, Futami K. Diagnosis and clinical course of ulcerative gastroduodenal lesion associated with ulcerative colitis: possible relationship with pouchitis. Dig Endosc. 2010;22:268-274. [PMID: 21175478 DOI: 10.1111/j.1443-1661.2010.01006.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
305 Wolff S, Terheggen G, Mueller R, Greinwald R, Franklin J, Kruis W. Are Endoscopic Endpoints Reliable in Therapeutic Trials of Ulcerative Colitis?: . Inflammatory Bowel Diseases 2013;19:2611-5. [DOI: 10.1097/01.mib.0000437044.43961.00] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
306 Paine ER. Colonoscopic evaluation in ulcerative colitis. Gastroenterol Rep (Oxf). 2014;2:161-168. [PMID: 24879406 DOI: 10.1093/gastro/gou028] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
307 Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'neil DA, Macfarlane GT. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005;54:242-249. [PMID: 15647189 DOI: 10.1136/gut.2004.044834] [Cited by in Crossref: 450] [Cited by in F6Publishing: 360] [Article Influence: 26.5] [Reference Citation Analysis]
308 Samuel S, Bruining DH, Loftus EV, Thia KT, Schroeder KW, Tremaine WJ, Faubion WA, Kane SV, Pardi DS, de Groen PC, Harmsen WS, Zinsmeister AR, Sandborn WJ. Validation of the Ulcerative Colitis Colonoscopic Index of Severity and Its Correlation With Disease Activity Measures. Clinical Gastroenterology and Hepatology 2013;11:49-54.e1. [DOI: 10.1016/j.cgh.2012.08.003] [Cited by in Crossref: 87] [Cited by in F6Publishing: 73] [Article Influence: 9.7] [Reference Citation Analysis]
309 d'Albasio G, Trallori G, Ghetti A, Milla M, Nucci A, Pacini F, Morettini A. Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. Diseases of the Colon & Rectum 1990;33:394-7. [DOI: 10.1007/bf02156265] [Cited by in Crossref: 46] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
310 Watts JM, Thompson H, Goligher JC. Sigmoidoscopy and cytology in the detection of microscopic disease of the rectal mucosa in ulcerative colitis. Gut 1966;7:288-94. [PMID: 18668808 DOI: 10.1136/gut.7.3.288] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
311 Grammatikopoulou MG, Gkiouras K, Theodoridis X, Asteriou E, Forbes A, Bogdanos DP. Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2018;10:E1737. [PMID: 30424514 DOI: 10.3390/nu10111737] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
312 Marshall JK. Reporting ileocolonoscopy in inflammatory bowel disease. Can J Gastroenterol 2006;20:399-400. [PMID: 16779456 DOI: 10.1155/2006/828236] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
313 Pineton de Chambrun G, Peyrin-biroulet L, Lémann M, Colombel J. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010;7:15-29. [DOI: 10.1038/nrgastro.2009.203] [Cited by in Crossref: 301] [Cited by in F6Publishing: 280] [Article Influence: 23.2] [Reference Citation Analysis]
314 Ray G. Inflammatory bowel disease in India--changing paradigms. Int J Colorectal Dis. 2011;26:635-644. [PMID: 21063715 DOI: 10.1007/s00384-010-1084-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
315 Millar AD, Rampton DS, Blake DR. Effects of iron and iron chelation in vitro on mucosal oxidant activity in ulcerative colitis. Aliment Pharmacol Ther 2000;14:1163-8. [PMID: 10971233 DOI: 10.1046/j.1365-2036.2000.00828.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.2] [Reference Citation Analysis]
316 Khanna R, Jairath V, Vande Casteele N, Mosli MH, Zou G, Parker CE, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG. Efficient Early Drug Development for Ulcerative Colitis. Gastroenterology 2016;150:1056-60. [PMID: 27018491 DOI: 10.1053/j.gastro.2016.03.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
317 Ket SN, Palmer R, Travis S. Endoscopic Disease Activity in Inflammatory Bowel Disease. Curr Gastroenterol Rep 2015;17:50. [PMID: 26650939 DOI: 10.1007/s11894-015-0470-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
318 Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1567-1574. [PMID: 16696804 DOI: 10.1111/j.1365-2036.2006.02927.x] [Cited by in Crossref: 277] [Cited by in F6Publishing: 237] [Article Influence: 17.3] [Reference Citation Analysis]
319 Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut. 2003;52:1587-1590. [PMID: 14570727 DOI: 10.1136/gut.5211.1587] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
320 Coulie B, Camilleri M, Bharucha AE, Sandborn WJ, Burton D. Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects. Aliment Pharmacol Ther. 2001;15:653-663. [PMID: 11328259 DOI: 10.1046/j.1365-2036.2001.00959.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 2.3] [Reference Citation Analysis]
321 Mitsuishi T. Correlation between histological findings and endoscopic findings in patients with ulcerative colitis: Basal plasmacytosis is an important finding suggesting active inflammation. JGH Open 2019;3:100-4. [PMID: 31061883 DOI: 10.1002/jgh3.12111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
322 Lee HJ, Kim YN, Jang HW, Jeon HH, Jung ES, Park SJ, Hong SP, Kim TI, Kim WH, Nam CM, Cheon JH. Correlations between endoscopic and clinical disease activity indices in intestinal Behcet's disease. World J Gastroenterol 2012; 18(40): 5771-5778 [PMID: 23155319 DOI: 10.3748/wjg.v18.i40.5771] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
323 Gutierrez Becker B, Arcadu F, Thalhammer A, Gamez Serna C, Feehan O, Drawnel F, Oh YS, Prunotto M. Training and deploying a deep learning model for endoscopic severity grading in ulcerative colitis using multicenter clinical trial data. Ther Adv Gastrointest Endosc. 2021;14:2631774521990623. [PMID: 33718871 DOI: 10.1177/2631774521990623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
324 Schippa S, Conte MP, Borrelli O, Iebba V, Aleandri M, Seganti L, Longhi C, Chiarini F, Osborn J, Cucchiara S. Dominant genotypes in mucosa-associated Escherichia coli strains from pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:661-672. [PMID: 19067417 DOI: 10.1002/ibd.20818] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
325 Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
326 Mahmood A, Melley L, Fitzgerald AJ, Ghosh S, Playford RJ. Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis. Aliment Pharmacol Ther. 2005;21:1357-1364. [PMID: 15932366 DOI: 10.1111/j.1365-2036.2005.02436.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
327 Ando T, Nishio Y, Watanabe O, Takahashi H, Maeda O, Ishiguro K, Ishikawa D, Ohmiya N, Niwa Y, Goto H. Value of colonoscopy for prediction of prognosis in patients with ulcerative colitis. World J Gastroenterol 2008; 14(14): 2133-2138 [PMID: 18407585 DOI: 10.3748/wjg.14.2133] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
328 Kugathasan S, Dubinsky MC, Keljo D, Moyer MS, Rufo PA, Wyllie R, Zachos M, Hyams J. Severe Colitis in Children: . Journal of Pediatric Gastroenterology and Nutrition 2005;41:375-85. [DOI: 10.1097/01.mpg.0000186272.65559.ce] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
329 Yokoyama H, Takagi S, Kuriyama S, Takahashi S, Takahashi H, Iwabuchi M, Takahashi S, Kinouchi Y, Hiwatashi N, Tsuji I. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis. 2007;13:1115-1120. [PMID: 17455207 DOI: 10.1002/ibd.20158] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
330 Edmonds CJ. Electrical potentials of the sigmoid colon and rectum in irritable bowel syndrome and ulcerative colitis. Gut 1970;11:867-74. [PMID: 4395004 DOI: 10.1136/gut.11.10.867] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 0.4] [Reference Citation Analysis]
331 Fite A, Macfarlane S, Furrie E, Bahrami B, Cummings JH, Steinke DT, Macfarlane GT. Longitudinal analyses of gut mucosal microbiotas in ulcerative colitis in relation to patient age and disease severity and duration. J Clin Microbiol. 2013;51:849-856. [PMID: 23269735 DOI: 10.1128/jcm.02574-12] [Cited by in Crossref: 63] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
332 Jitsumura M, Kokelaar RF, Harris DA. Remission endpoints in ulcerative colitis: A systematic review. World J Meta-Anal 2017; 5(4): 85-102 [DOI: 10.13105/wjma.v5.i4.85] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
333 Egan LJ, Sandborn WJ, Mays DC, Tremaine WJ, Lipsky JJ. Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate. Inflamm Bowel Dis. 1999;5:167-173. [PMID: 10453372 DOI: 10.1097/00054725-199908000-00004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
334 Dimitroulia E, Pitiriga VC, Piperaki ET, Spanakis NE, Tsakris A. Inflammatory bowel disease exacerbation associated with Epstein-Barr virus infection. Dis Colon Rectum. 2013;56:322-327. [PMID: 23392146 DOI: 10.1097/dcr.0b013e31827cd02c] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
335 Irvine EJ. Quality of Life–Measurement in Inflammatory Bowel Disease. Scandinavian Journal of Gastroenterology 2009;28:36-9. [DOI: 10.3109/00365529309098355] [Cited by in Crossref: 43] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
336 Polese L, Angriman I, Franchis GD, Cecchetto A, Sturniolo GC, D’Incà R, Scarpa M, Ruffolo C, Norberto L, Frego M, D’Amico DF. Persistence of high CD40 and CD40L expression after restorative proctocolectomy for ulcerative colitis. World J Gastroenterol 2005; 11(34): 5303-5308 [PMID: 16149136 DOI: 10.3748/wjg.v11.i34.5303] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
337 Jowett SL, Seal CJ, Barton JR, Welfare MR. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol. 2001;96:2921-2928. [PMID: 11693327 DOI: 10.1111/j.1572-0241.2001.04682.x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 117] [Article Influence: 6.0] [Reference Citation Analysis]
338 Moriichi K, Fujiya M, Okumura T. The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease. Dig Endosc 2021;33:1008-23. [PMID: 33020947 DOI: 10.1111/den.13863] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
339 Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, Andrews E, Ajami NJ, Bonham KS, Brislawn CJ, Casero D, Courtney H, Gonzalez A, Graeber TG, Hall AB, Lake K, Landers CJ, Mallick H, Plichta DR, Prasad M, Rahnavard G, Sauk J, Shungin D, Vázquez-Baeza Y, White RA 3rd, Braun J, Denson LA, Jansson JK, Knight R, Kugathasan S, McGovern DPB, Petrosino JF, Stappenbeck TS, Winter HS, Clish CB, Franzosa EA, Vlamakis H, Xavier RJ, Huttenhower C; IBDMDB Investigators. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 2019;569:655-62. [PMID: 31142855 DOI: 10.1038/s41586-019-1237-9] [Cited by in Crossref: 555] [Cited by in F6Publishing: 484] [Article Influence: 185.0] [Reference Citation Analysis]
340 Rask-Madsen J. Sieving characteristics of inflamed rectal mucosa. Gut 1973;14:988-9. [PMID: 4785288 DOI: 10.1136/gut.14.12.988] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
341 Rampton DS, Barton TP. Are prostaglandins cytoprotective in the human large intestine?—the effect of indomethacin on rectal mucosal function and prostaglandin E2 releasein vivo. Agents and Actions 1984;14:715-8. [DOI: 10.1007/bf01978913] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
342 Hirai F, Matsui T. A critical review of endoscopic indices in ulcerative colitis: inter-observer variation of the endoscopic index. Clin J Gastroenterol 2008;1:40-5. [PMID: 26193460 DOI: 10.1007/s12328-008-0018-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
343 American Society for Gastrointestinal Endoscopy Standards of Practice Committee. , Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Evans JA, Fanelli RD, Fisher DA, Fonkalsrud L, Foley K, Hwang JH, Jue TL, Khashab MA, Muthusamy VR, Pasha SF, Saltzman JR, Sharaf R, Cash BD, DeWitt JM. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 2015; 81: 1101-21. e1-13. [PMID: 25800660 DOI: 10.1016/j.gie.2014.10.030] [Cited by in Crossref: 172] [Cited by in F6Publishing: 152] [Article Influence: 24.6] [Reference Citation Analysis]
344 Vaughn BP, Shah S, Cheifetz AS. The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol 2014;12:103-17. [PMID: 24395615 DOI: 10.1007/s11938-013-0008-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
345 Giacomelli R, Passacantando A, Frieri G, Parzanese I, D'Alò S, Vernia P, Pimpo MT, Petrucci C, Caprilli R, Cifone MG. Circulating soluble factor-inhibiting natural killer (NK) activity of fresh peripheral blood mononuclear cells (PBMC) from inflammatory bowel disease (IBD) patients. Clin Exp Immunol. 1999;115:72-77. [PMID: 9933422 DOI: 10.1046/j.1365-2249.1999.00741.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.6] [Reference Citation Analysis]
346 Tonelli F, Bianchini F, Lodovici M, Valanzano R, Caderni G, Dolara P. Mucosal cell proliferation of the rectal stump in ulcerative colitis patients after ileorectal anastomosis. Diseases of the Colon & Rectum 1991;34:385-90. [DOI: 10.1007/bf02053688] [Cited by in Crossref: 7] [Article Influence: 0.2] [Reference Citation Analysis]
347 Kedia S, Bhatia V, Thareja S, Garg S, Mouli VP, Bopanna S, Tiwari V, Makharia G, Ahuja V. Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial. World J Gastrointest Pharmacol Ther 2017; 8(2): 147-154 [PMID: 28533925 DOI: 10.4292/wjgpt.v8.i2.147] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
348 Boal Carvalho P, Dias de Castro F, Rosa B, Moreira MJ, Cotter J. Mucosal Healing in Ulcerative Colitis--When Zero is Better. J Crohns Colitis. 2016;10:20-25. [PMID: 26438714 DOI: 10.1093/ecco-jcc/jjv180] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
349 Andersson P, Norblad R, Söderholm JD, Myrelid P. Ileorectal anastomosis in comparison with ileal pouch anal anastomosis in reconstructive surgery for ulcerative colitis--a single institution experience. J Crohns Colitis. 2014;8:582-589. [PMID: 24315777 DOI: 10.1016/j.crohns.2013.11.014] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
350 Stack BH, Smith T, Jones JH, Fletcher J. Measurement of blood and iron loss in colitis with a whole-body counter. Gut 1969;10:769-73. [PMID: 5307623 DOI: 10.1136/gut.10.10.769] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
351 Pica R, Cassieri C, Cocco A, Zippi M, Marcheggiano A, De Nitto D, Avallone EV, Crispino P, Occhigrossi G, Paoluzi P. A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis. Dig Liver Dis 2015;47:933-7. [PMID: 26391602 DOI: 10.1016/j.dld.2015.07.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
352 Dearling JL, Park EJ, Dunning P, Baker A, Fahey F, Treves ST, Soriano SG, Shimaoka M, Packard AB, Peer D. Detection of intestinal inflammation by MicroPET imaging using a (64)Cu-labeled anti-beta(7) integrin antibody. Inflamm Bowel Dis 2010;16:1458-66. [PMID: 20186943 DOI: 10.1002/ibd.21231] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
353 Hisabe T, Ninomiya K, Matsui T, Karashima Y, Sato Y, Nagahama T, Takaki Y, Hirai F, Yao K, Higashi D. Small bowel lesions detected with wireless capsule endoscopy in patients with active ulcerative colitis and with post-proctocolectomy. Dig Endosc. 2011;23:302-309. [PMID: 21951090 DOI: 10.1111/j.1443-1661.2011.01149.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
354 Lan YZ, Bai YL, Zhu XD. Integrated Traditional Chinese and Western medicine for ulcerative colitis with diabetes: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e24444. [PMID: 33530250 DOI: 10.1097/MD.0000000000024444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
355 Guimbaud R, Izzo A, Martinolle JP, Vidon N, Couturier D, Benveniste J, Chaussade S. Intraluminal excretion of PAF, lysoPAF, and acetylhydrolase in patients with ulcerative colitis. Dig Dis Sci. 1995;40:2635-2640. [PMID: 8536524 DOI: 10.1007/bf02220453] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
356 Denton A, Forbes A, Andreyev J, Maher EJ. Non surgical interventions for late radiation proctitis in patients who have received radical radiotherapy to the pelvis. Cochrane Database Syst Rev 2002;:CD003455. [PMID: 11869662 DOI: 10.1002/14651858.CD003455] [Cited by in Crossref: 48] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
357 Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, Taylor CJ, Evans GS. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology. 1999;117:814-822. [PMID: 10500063 DOI: 10.1016/s0016-5085(99)70339-2] [Cited by in Crossref: 219] [Cited by in F6Publishing: 94] [Article Influence: 9.5] [Reference Citation Analysis]
358 Hawthorne AB, Record CO, Holdsworth CD, Giaffer MH, Burke DA, Keech ML, Hawkey CJ. Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis. Gut. 1993;34:125-128. [PMID: 8432442 DOI: 10.1136/gut.34.1.125] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 1.3] [Reference Citation Analysis]
359 Christensen B, Rubin DT. Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. Curr Gastroenterol Rep 2016;18. [DOI: 10.1007/s11894-015-0477-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
360 Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009; 137: 1934-43. e1-3. [PMID: 19766640 DOI: 10.1053/j.gastro.2009.08.069] [Cited by in Crossref: 105] [Cited by in F6Publishing: 93] [Article Influence: 8.1] [Reference Citation Analysis]
361 Brahmania M, Bernstein CN. Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitis. Can J Gastroenterol Hepatol 2014;28:325-9. [PMID: 24945187 DOI: 10.1155/2014/737349] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
362 Li F, Zou Y, Li X. Up-regulation of signal transducer and activator of transcription-3 is associated with aggravation of ulcerative colitis. Surgeon. 2010;8:262-266. [PMID: 20709283 DOI: 10.1016/j.surge.2010.03.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
363 Schlup M, Chang A, Chadwick D, Ferry D, Chadwick V. Potential of Measurements of Unsaturated Vitamin B 12 -Binding Capacity in Serial Colonoscopic Biopsy Specimens for Global and Regional Assessments of Disease Severity in Inflammatory Bowel Disease. Scandinavian Journal of Gastroenterology 2009;28:1005-10. [DOI: 10.3109/00365529309098300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
364 Tsuda S, Carreras J, Kikuti YY, Nakae H, Dekiden-Monma M, Imai J, Tsuruya K, Nakamura J, Tsukune Y, Uchida T, Matsushima M, Roncador G, Suzuki T, Nakamura N, Mine T. Prediction of steroid demand in the treatment of patients with ulcerative colitis by immunohistochemical analysis of the mucosal microenvironment and immune checkpoint: role of macrophages and regulatory markers in disease severity. Pathol Int 2019;69:260-71. [PMID: 30990953 DOI: 10.1111/pin.12794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
365 Iheozor-Ejiofor Z, Kaur L, Gordon M, Baines PA, Sinopoulou V, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2020;3:CD007443. [PMID: 32128794 DOI: 10.1002/14651858.CD007443.pub3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
366 Carty E, Nickols C, Feakins RM, Rampton DS. Thromboxane synthase immunohistochemistry in inflammatory bowel disease. J Clin Pathol 2002;55:367-70. [PMID: 11986343 DOI: 10.1136/jcp.55.5.367] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
367 Zissis M, Afroudakis A, Galanopoulos G, Palermos L, Boura X, Michopoulos S, Archimandritis A. B2 microglobulin: is it a reliable marker of activity in inflammatory bowel disease? Am J Gastroenterol. 2001;96:2177-2183. [PMID: 11467650 DOI: 10.1111/j.1572-0241.2001.03881.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
368 Hawthorne AB, Stenson R, Gillespie D, Swarbrick ET, Dhar A, Kapur KC, Hood K, Probert CS. One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflamm Bowel Dis 2012;18:1885-93. [PMID: 22081522 DOI: 10.1002/ibd.21938] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
369 Pagnini C, Menasci F, Desideri F, Corleto VD, Delle Fave G, Di Giulio E. Endoscopic scores for inflammatory bowel disease in the era of ‘mucosal healing’: Old problem, new perspectives. Digestive and Liver Disease 2016;48:703-8. [DOI: 10.1016/j.dld.2016.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
370 de Lange T, Larsen S, Aabakken L. Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis. BMC Gastroenterol. 2004;4:9. [PMID: 15149550 DOI: 10.1186/1471-230x-4-9] [Cited by in Crossref: 46] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
371 Crispino P, Habib FI, Badiali D, Pica R, Iacopini F, Bella A, Cassieri C, Anzini F, Paoluzi P. Colorectal motor and sensitivity features in patients affected by ulcerative proctitis with constipation: a radiological and manometric controlled study. Inflamm Bowel Dis 2006;12:712-8. [PMID: 16917226 DOI: 10.1097/00054725-200608000-00007] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
372 Matsumoto T, Kuroki F, Mizuno M, Nakamura S, Iida M. Application of magnifying chromoscopy for the assessment of severity in patients with mild to moderate ulcerative colitis. Gastrointest Endosc. 1997;46:400-405. [PMID: 9402112 DOI: 10.1016/S0016-5107(97)70031-2] [Cited by in Crossref: 53] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
373 Manes G, Imbesi V, Ardizzone S, Cassinotti A, Bosani M, Massari A, Porro GB. Appropriateness and diagnostic yield of colonoscopy in the management of patients with ulcerative colitis: A prospective study in an open access endoscopy service: . Inflammatory Bowel Diseases 2008;14:1133-8. [DOI: 10.1002/ibd.20434] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
374 Carty E, Macey M, McCartney SA, Rampton DS. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: anti-inflammatory profile in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:807-17. [PMID: 10848666 DOI: 10.1046/j.1365-2036.2000.00779.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
375 Ang YS, Mahmud N, White B, Byrne M, Kelly A, Lawler M, McDonald GS, Smith OP, Keeling PW. Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14:1015-1022. [PMID: 10930895 DOI: 10.1046/j.1365-2036.2000.00802.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 2.9] [Reference Citation Analysis]
376 Smith RL, Taylor KM, Friedman AB, Gibson RN, Gibson PR. Systematic Review: Clinical Utility of Gastrointestinal Ultrasound in the Diagnosis, Assessment and Management of Patients With Ulcerative Colitis. J Crohns Colitis 2020;14:465-79. [PMID: 31562739 DOI: 10.1093/ecco-jcc/jjz163] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
377 Jung SA. Differential diagnosis of inflammatory bowel disease: what is the role of colonoscopy? Clin Endosc 2012;45:254-62. [PMID: 22977813 DOI: 10.5946/ce.2012.45.3.254] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
378 Khan Z, Macdonald C, Wicks AC, Holt MP, Floyd D, Ghosh S, Wright NA, Playford RJ. Use of the 'nutriceutical', bovine colostrum, for the treatment of distal colitis: results from an initial study. Aliment Pharmacol Ther 2002;16:1917-22. [PMID: 12390100 DOI: 10.1046/j.1365-2036.2002.01354.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
379 Pagnini C, Menasci F, Festa S, Rizzatti G, Fave GD. “Mucosal healing” in ulcerative colitis: Between clinical evidence and market suggestion. World J Gastrointest Pathophysiol 2014; 5(2): 54-62 [PMID: 24891976 DOI: 10.4291/wjgp.v5.i2.54] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
380 Langmead L, Feakins RM, Goldthorpe S, Holt H, Tsironi E, De Silva A, Jewell DP, Rampton DS. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther. 2004;19:739-747. [PMID: 15043514 DOI: 10.1111/j.1365-2036.2004.01902.x] [Cited by in Crossref: 156] [Cited by in F6Publishing: 113] [Article Influence: 8.7] [Reference Citation Analysis]
381 Seidner DL, Lashner BA, Brzezinski A, Banks PL, Goldblum J, Fiocchi C, Katz J, Lichtenstein GR, Anton PA, Kam LY. An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol. 2005;3:358-369. [PMID: 15822041 DOI: 10.1016/s1542-3565(04)00672-x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
382 Bharadwaj S, Tandon P, Kulkarni G, Rivas J, Charles R. The role of endoscopy in inflammatory bowel disease. J Dig Dis. 2015;16:689-698. [PMID: 26595156 DOI: 10.1111/1751-2980.12301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
383 Kobayashi K, Hirai F, Naganuma M, Watanabe K, Ando T, Nakase H, Matsuoka K, Watanabe M. A randomized clinical trial of mesalazine suppository: the usefulness and problems of central review of evaluations of colonic mucosal findings. J Crohns Colitis 2014;8:1444-53. [PMID: 24923656 DOI: 10.1016/j.crohns.2014.05.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
384 Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). Gastrointestinal Endoscopy 2020;91:733-45. [DOI: 10.1016/j.gie.2019.11.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
385 Samaan MA, Mosli MH, Sandborn WJ, Feagan BG, D' Haens GR, Dubcenco E, Baker KA, Levesque BG. A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. Inflamm Bowel Dis. 2014;20:1465-1471. [PMID: 24831558 DOI: 10.1097/mib.0000000000000046] [Cited by in Crossref: 51] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
386 Davies PS, Rhodes J, Counsell B, Heatley RV, Newcombe RG. A nitroindanedione mast cell stabiliser in the treatment of ulcerative colitis: a controlled trial. Clin Allergy 1979;9:373-6. [PMID: 383311 DOI: 10.1111/j.1365-2222.1979.tb02495.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
387 Gomes P, du Boulay C, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut. 1986;27:92-95. [PMID: 3949241 DOI: 10.1136/gut.27.1.92] [Cited by in Crossref: 246] [Cited by in F6Publishing: 235] [Article Influence: 6.8] [Reference Citation Analysis]
388 Kyösola K, Penttilä O, Salaspuro M. Rectal mucosal adrenergic innervation and enterochromaffin cells in ulcerative colitis and irritable colon. Scand J Gastroenterol. 1977;12:363-367. [PMID: 867000 DOI: 10.3109/00365527709180942] [Cited by in Crossref: 79] [Cited by in F6Publishing: 76] [Article Influence: 1.8] [Reference Citation Analysis]
389 Magee EA, Edmond LM, Tasker SM, Kong SC, Curno R, Cummings JH. Associations between diet and disease activity in ulcerative colitis patients using a novel method of data analysis. Nutr J. 2005;4:7. [PMID: 15705205 DOI: 10.1186/1475-2891-4-7] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 3.4] [Reference Citation Analysis]
390 Fox J, Vidins E, Beck I. Observer Variation in Esophageal Pressure Assessment. Gastroenterology 1973;65:884-8. [DOI: 10.1016/s0016-5085(19)32979-8] [Cited by in Crossref: 12] [Article Influence: 0.2] [Reference Citation Analysis]
391 Thia KT, Loftus EV, Pardi DS, Kane SV, Faubion WA, Tremaine WJ, Schroeder KW, Harmsen SW, Zinsmeister AR, Sandborn WJ. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis. 2011;17:1257-1264. [PMID: 20878712 DOI: 10.1002/ibd.21480] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
392 Paoluzi P, D'Albasio G, Pera A, Bianchi Porro G, Paoluzi OA, Pica R, Cottone M, Miglioli M, Prantera C, Sturniolo G. Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Dig Liver Dis. 2002;34:787-793. [PMID: 12546514 DOI: 10.1016/s1590-8658(02)80072-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
393 Shen J, Ran ZH, Zhang Y, Cai Q, Yin HM, Zhou XT, Xiao SD. Biomarkers of altered coagulation and fibrinolysis as measures of disease activity in active inflammatory bowel disease: a gender-stratified, cohort analysis. Thromb Res 2009;123:604-11. [PMID: 18499234 DOI: 10.1016/j.thromres.2008.04.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
394 Banerjee D, Deb R, Dar L, Mirdha BR, Pati SK, Thareja S, Falodia S, Ahuja V. High frequency of parasitic and viral stool pathogens in patients with active ulcerative colitis: report from a tropical country. Scand J Gastroenterol. 2009;44:325-331. [PMID: 19040190 DOI: 10.1080/00365520802556809] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
395 Schmidt C, Giese T, Ludwig B, Mueller-Molaian I, Marth T, Zeuzem S, Meuer SC, Stallmach A. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn’s disease but not in ulcerative colitis. Inflamm Bowel Dis. 2005;11:16-23. [PMID: 15674109 DOI: 10.1097/00054725-200501000-00003] [Cited by in Crossref: 206] [Cited by in F6Publishing: 203] [Article Influence: 12.1] [Reference Citation Analysis]
396 Abdalla M, Norblad R, Olsson M, Landerholm K, Andersson P, Söderholm JD, Andersson R, Myrelid P. Anorectal Function After Ileo-Rectal Anastomosis Is Better than Pelvic Pouch in Selected Ulcerative Colitis Patients. Dig Dis Sci 2020;65:250-9. [PMID: 31372911 DOI: 10.1007/s10620-019-05757-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
397 Sakuraba A, Sato T, Naganuma M, Morohoshi Y, Matsuoka K, Inoue N, Takaishi H, Ogata H, Iwao Y, Hibi T. A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis. J Gastroenterol. 2008;43:51-56. [PMID: 18297436 DOI: 10.1007/s00535-007-2129-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
398 Pallis AG, Mouzas IA, Vlachonikolis IG. The inflammatory bowel disease questionnaire: a review of its national validation studies. Inflamm Bowel Dis. 2004;10:261-269. [PMID: 15290922 DOI: 10.1097/00054725-200405000-00014] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 2.9] [Reference Citation Analysis]
399 Carter MJ, Jones S, Camp NJ, Cox A, Mee J, Warren B, Duff GW, Lobo AJ, di Giovine FS. Functional correlates of the interleukin-1 receptor antagonist gene polymorphism in the colonic mucosa in ulcerative colitis. Genes Immun. 2004;5:8-15. [PMID: 14735144 DOI: 10.1038/sj.gene.6364032] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
400 Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand? Curr Gastroenterol Rep. 2010;12:471-478. [PMID: 20886319 DOI: 10.1007/s11894-010-0146-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
401 Minoli G, Pera A, Barletti C, Vanni R, Rocca R. Endoscopy concordance in diagnosis of IBD. Acta Endosc 1990;20:273-7. [DOI: 10.1007/bf02966297] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
402 Polson RJ, Misiewicz JJ. Medical management of severe inflammatory disease of the rectum and distal colon: non-nutritional aspects. Baillieres Clin Gastroenterol 1992;6:1-26. [PMID: 1586763 DOI: 10.1016/0950-3528(92)90015-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.0] [Reference Citation Analysis]
403 Schmidt C, Giese T, Goebel R, Schilling M, Marth T, Ruether A, Schreiber S, Zeuzem S, Meuer SC, Stallmach A. Interleukin-18 is increased only in a minority of patients with active Crohn's disease. Int J Colorectal Dis. 2007;22:1013-1020. [PMID: 17318554 DOI: 10.1007/s00384-007-0282-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
404 Watkinson G. Ulcerative Colitis. Scott Med J 1970;15:184-94. [DOI: 10.1177/003693307001500505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
405 Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, Harrison JM, Zinsmeister AR. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994;106:1429-35. [DOI: 10.1016/0016-5085(94)90394-8] [Cited by in Crossref: 97] [Cited by in F6Publishing: 83] [Article Influence: 3.5] [Reference Citation Analysis]
406 Elliott TR, Rayment NB, Hudspith BN, Hands RE, Taylor K, Parkes GC, Prescott NJ, Petrovska L, Hermon-Taylor J, Brostoff J, Boussioutas A, Mathew CG, Bustin SA, Sanderson JD. Lamina propria macrophage phenotypes in relation to Escherichia coli in Crohn's disease. BMC Gastroenterol 2015;15:75. [PMID: 26137941 DOI: 10.1186/s12876-015-0305-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
407 Picco MF, Krishna M, Cangemi JR, Shelton D. Oral mesalamine and clinical remission are associated with a decrease in the extent of long-standing ulcerative colitis: . Inflammatory Bowel Diseases 2006;12:537-42. [DOI: 10.1097/01.ibd.0000225345.29603.7d] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
408 D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786. [PMID: 17258735 DOI: 10.1053/j.gastro.2006.12.038] [Cited by in Crossref: 629] [Cited by in F6Publishing: 562] [Article Influence: 39.3] [Reference Citation Analysis]
409 Kumar S, Ghoshal UC, Aggarwal R, Saraswat VA, Choudhuri G. Severe ulcerative colitis: prospective study of parameters determining outcome. J Gastroenterol Hepatol. 2004;19:1247-1252. [PMID: 15482530 DOI: 10.1111/j.1440-1746.2004.03486.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
410 Hawkey CJ, Rampton DS. Benoxaprofen in the treatment of active ulcerative colitis. Prostaglandins Leukot Med 1983;10:405-9. [PMID: 6407032 DOI: 10.1016/0262-1746(83)90052-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.5] [Reference Citation Analysis]
411 Meenan J, Spaans J, Grool TA, Pals ST, Tytgat GN, van Deventer SJ. Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation. Gut. 1997;40:241-246. [PMID: 9071939 DOI: 10.1136/gut.40.2.241] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 2.7] [Reference Citation Analysis]
412 Slovak JE, Wang C, Morrison JA, Deitz KL, LeVine DN, Otoni C, King RR, Gerber LE, Hanson KR, Lundberg AP, Jergens AE. Endoscopic assessment of the duodenum in dogs with inflammatory bowel disease. J Vet Intern Med 2014;28:1442-6. [PMID: 25274438 DOI: 10.1111/jvim.12424] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
413 Gionchetti P, Ardizzone S, Benvenuti ME, Bianchi Porro G, Biasco G, Cesari P, D'albasio G, De Franchis R, Monteleone G, Pallone F. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther. 1999;13:381-388. [PMID: 10102972 DOI: 10.1046/j.1365-2036.1999.00482.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 2.0] [Reference Citation Analysis]
414 Hodgson HJF, Bhatti M. Assessment of disease activity in ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 1995;1:117-34. [DOI: 10.1002/ibd.3780010206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
415 Kristjánsson G, Venge P, Wanders A, Lööf L, Hällgren R. Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut. 2004;53:1806-1812. [PMID: 15542519 DOI: 10.1136/gut.2003.036418] [Cited by in Crossref: 61] [Cited by in F6Publishing: 69] [Article Influence: 3.4] [Reference Citation Analysis]
416 Creed TJ, Norman MR, Probert CS, Harvey RF, Shaw IS, Smithson J, Anderson J, Moorghen M, Gupta J, Shepherd NA. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther. 2003;18:65-75. [PMID: 12848627 DOI: 10.1046/j.1365-2036.2003.01639.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 77] [Article Influence: 4.7] [Reference Citation Analysis]
417 Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Colonic prostaglandin E2 levels and olsalazine metabolism in relapsing ulcerative colitis: implications for controlled trials in the long term. Scand J Gastroenterol Suppl 1988;148:76-80. [PMID: 3067341 DOI: 10.3109/00365528809101554] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
418 Elliott TR, Hudspith BN, Wu G, Cooley M, Parkes G, Quiñones B, Randall L, Mandrell RE, Fagerquist CK, Brostoff J, Rayment NB, Boussioutas A, Petrovska L, Sanderson JD. Quantification and characterization of mucosa-associated and intracellular Escherichia coli in inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2326-38. [PMID: 23989750 DOI: 10.1097/MIB.0b013e3182a38a92] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
419 Kochhar R, Mehta SK, Aggarwal R, Dhar A, Patel F. Sucralfate enema in ulcerative rectosigmoid lesions. Dis Colon Rectum 1990;33:49-51. [PMID: 2295277 DOI: 10.1007/BF02053202] [Cited by in Crossref: 48] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
420 Gordon FH, Hamilton MI, Donoghue S, Greenlees C, Palmer T, Rowley-Jones D, Dhillon AP, Amlot PL, Pounder RE. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther. 2002;16:699-705. [PMID: 11929387 DOI: 10.1046/j.1365-2036.2002.01205.x] [Cited by in Crossref: 122] [Cited by in F6Publishing: 107] [Article Influence: 6.1] [Reference Citation Analysis]
421 Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, Scott BB, Lennard-Jones JE. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305:20-22. [PMID: 1638191 DOI: 10.1136/bmj.305.6844.20] [Cited by in Crossref: 322] [Cited by in F6Publishing: 288] [Article Influence: 10.7] [Reference Citation Analysis]
422 Conn H, Binder H, Brodoff M. Fiberoptic and Conventional Esophagoscopy in the Diagnosis of Esophageal Varices. Gastroenterology 1967;52:810-8. [DOI: 10.1016/s0016-5085(67)80068-4] [Cited by in Crossref: 19] [Article Influence: 0.3] [Reference Citation Analysis]
423 Dai L, Tang Y, Zhou W, Dang Y, Sun Q, Tang Z, Zhu M, Ji G. Gut Microbiota and Related Metabolites Were Disturbed in Ulcerative Colitis and Partly Restored After Mesalamine Treatment. Front Pharmacol 2020;11:620724. [PMID: 33628183 DOI: 10.3389/fphar.2020.620724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
424 Gjørup T, Agner E, Jensen LB, Jensen AM, Møllmann K. The Endoscopic Diagnosis of Duodenal Ulcer Disease: A Randomized Clinical Trial of Bias and of Interobserver Variation. Scandinavian Journal of Gastroenterology 2009;21:261-7. [DOI: 10.3109/00365528609003074] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
425 Almer S, Franzén L, Peters AM, Tjädermo M, Ekberg S, Granerus G, Ström M. Do Technetium-99m Hexamethylpropylene Amine Oxime-Labeled Leukocytes Truly Reflect the Mucosal Inflammation in Patients with Ulcerative Colitis? Scandinavian Journal of Gastroenterology 2009;27:1031-8. [DOI: 10.3109/00365529209028134] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
426 Jones JL, Foxx-Orenstein AE. The role of probiotics in inflammatory bowel disease. Dig Dis Sci 2007;52:607-11. [PMID: 17235706 DOI: 10.1007/s10620-006-9225-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
427 Giacomelli R, Passacantando A, Parzanese I, Cucinelli F, Klidara N, Lattanzio R, Santori E, Paolini F, Manetti L, D'alo S, Cipriani P, Cifone M, Tonietti G. γ/δ T Cells are not Involved in the Natural and Antibody-Dependent Cytotoxicity of Peripheral blood Mononuclear Cells in Inflammatory Bowel Disease. Int J Immunopathol Pharmacol 1997;10:183-8. [DOI: 10.1177/039463209701000303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
428 Lobatón T, Bessissow T, De Hertogh G, Lemmens B, Maedler C, Van Assche G, Vermeire S, Bisschops R, Rutgeerts P, Bitton A. The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. J Crohns Colitis. 2015;9:846-852. [PMID: 26116558 DOI: 10.1093/ecco-jcc/jjv111] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
429 Jayson MI, Salmon PR, Harrison WJ. Inflammatory bowel disease in ankylosing spondylitis. Gut 1970;11:506-11. [PMID: 5430378 DOI: 10.1136/gut.11.6.506] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 0.7] [Reference Citation Analysis]
430 D’Incà R, Barollo M, Scarpa M, Grillo AR, Brun P, Vettorato MG, Castagliuolo I, Sturniolo GC. Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. Dig Dis Sci. 2011;56:1178-1187. [PMID: 20737210 DOI: 10.1007/s10620-010-1384-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
431 Yadav DP, Kedia S, Madhusudhan KS, Bopanna S, Goyal S, Jain S, Vikram NK, Sharma R, Makharia GK, Ahuja V. Body Composition in Crohn's Disease and Ulcerative Colitis: Correlation with Disease Severity and Duration.Can J Gastroenterol Hepatol. 2017;2017:1215035. [PMID: 29226115 DOI: 10.1155/2017/1215035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]